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ABSTRACT 
 
The EC1 protein has an important role in the E-cadherin mediated cell-cell 
adhesion in epithelial and endothelial tissues. It may be used as modulator of cellular 
adhesion to improve paracellular delivery of macromolecules. EC1 undergoes 
oxidation of its Cys residue to form disulfide-linked covalent dimers. These dimers 
associate to form physical oligomers. The dimerization and oligomerization also lead 
to hydrolysis of the Asp93–Pro94 peptide bond and precipitation. To be able to study 
the cell adhesion-modulating activity of EC1, it is important that we block its 
disulfide-dimerization and subsequent oligomerization. 
The strategies used to block the dimerization were addition of dithiothreitol to the 
EC1 solution, modification of the Cys thiol with iodoacetamide and polyethylene 
glycol. These derivatives were studied for their stability using HPLC, CD and 
fluorescence spectroscopy. All strategies applied showed improvement in the stability 
of EC1. The PEGylated EC1 showed the best stability.  
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1.1. Introduction 
The use of proteins for therapeutic applications has increased dramatically in the 
last several decades. There has been a tremendous increase in the number of approved 
drugs derived from recombinant proteins and monoclonal antibodies since the 
approval of recombinant insulin in 1982 (Figure 1.1).1 In addition, the number of 
approved indications is almost four times the number of approved drugs in 2005. 
Sales of protein drugs in 2008 are estimated to be around 71 billion USD.2 Thus, 
many proteins are currently being investigated for use as therapeutic agents for 
different diseases (i.e., cancer, autoimmune diseases). Most of the approved protein 
drugs that are commercially available are administered parenterally. This is due to the 
fact that proteins have very low bioavailability when administered orally. The low 
bioavailability of orally administered proteins is partly due to their chemical 
breakdown under the highly acidic conditions in the stomach and the mildly acidic to 
mildly basic conditions in the small intestine, and partly due to their very low 
absorption across the intestinal epithelium. The transcellular pathway is not a viable 
option for the absorption of proteins across the intestinal epithelia into the blood 
stream due to the highly charged nature of proteins. The absorption of proteins 
through the paracellular pathway, which utilizes the intercellular space for 
permeation, is also limited due to the presence of intercellular junctions. These 
junctions are formed through the interactions of various transmembrane proteins. One 
 3
such protein is E-cadherin. The C-terminal region of E-cadherins is located in the 
cytoplasm, whereas the N-terminal region is located in the extracellular matrix. This  
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Figure 1.1: Increasing trend in the use of recombinant proteins and monoclonal 
antibodies as drugs. The number of new biotech drugs and new indications approved 
for biotech drugs from 1982 to 2005. 
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extracellular portion of E-cadherins is composed of five sub-domains, called EC1 
through EC5. EC1 is the most N-terminal sub-domain and located farthest away from 
the cell surface. The extracellular portions of E-cadherins from the same cell surface 
interact to form cis-dimers; cis-dimers from opposite cell surfaces interact to produce 
trans-oligomers,3-5 resulting in cell-cell adhesion. The EC1 subdomain of E-cadherins 
has been shown to be essential for the homophilic selectivity of E-cadherins.6-12 
Therefore, in theory, EC1 can be used to modulate the E-cadherin interactions in the 
intercellular junctions, thereby improving paracellular transport of protein 
therapeutics. Thus, our long-term goal is to study the possibility of employing EC1 as 
a modulator of E-cadherin interactions. In fact, peptides with sequences derived from 
EC1 have been shown to increase the transport of mannitol, which is a paracellular 
marker.13 We will like to conduct in vitro studies in cultured cell monolayers to study 
the activity of EC1. 
For this purpose, recombinant human EC1 was expressed in our laboratory.14 The 
yield of the expression system was found to be low (about 2 mg EC1/L of 
fermentation medium used).  In solution, EC1 was shown to produce covalent dimers 
by the formation of intermolecular disulfide bonds between the Cys9 residues of EC1 
monomers.15 Furthermore, the formation of non-covalent oligomers was also 
observed. Interestingly, it was found that when dithiothreitol (DTT), a thiol reducing 
agent, was added to the solution, the covalent dimers as well as the physical 
 5
oligomers converted to monomers of EC1. Therefore, it was concluded that formation 
of disulfide-linked dimers of EC1 was essential to the formation of physical 
oligomers of EC1. Thus, the EC1 solution, in the absence of a reducing agent, was a 
heterogenous mixture of monomers, covalent dimers and physical oligomers. It would 
be undesirable to have these different forms of EC1 in solution when performing 
biological activity assays of EC1, because one or more of these forms of EC1 could 
be inactive or worse, have a detrimental effect on the activity assay. Consequently, 
we decided to survey the literature for different approaches applied to overcome the 
problem of disulfide formation.  In the following sections, we have assimilated the 
relevant information on disulfides and thiols in proteins. We describe how protein 
disulfide bonds are produced in prokaryotic and eukaryotic cells, followed by how 
oxidative folding of reduced denatured proteins can be achieved in vitro, the effect of 
disulfide bonds on protein stability, various qualitative and quantitative methods used 
to assay protein thiols and disulfides, chemical degradation reactions of protein 
disulfides in solution and finally, various methods that can be used to modify protein 
thiols so as to block their oxidation to disulfides.  
 
1.2. Disulfide bond formation as a post-translational modification of proteins 
Native disulfide bonds in proteins are assembled during the oxidative folding 
process. In eukaryotes, this process occurs in the endoplasmic reticulum (ER) 
lumen,16 whereas in prokaryotes it takes place in the periplasm.17 Thus, disulfide 
bonds are usually formed only in specific cellular compartments in healthy cells. 
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Proteins synthesized by ribosomes are in reduced and unfolded form, and their 
oxidative refolding in eukaryotes is aided by a series of enzymes such as the 
endoplasmic reticulum oxireductin-1 (Ero1), protein disulfide isomerases (PDI) and 
Erv2.16,18-20 Many of these enzymes possess C-X-X-C (i.e., PDI) and C-X-C (i.e., 
Erv2) motifs that are involved in thiol-disulfide redox exchange reactions.21 PDI 
directly oxidizes thiol groups in a protein via a series of thiol-disulfide exchange 
reactions by partnering with Ero1 or Erv2. The Ero1 enzyme, which is found inside 
the ER and is associated with the ER membrane, oxidizes PDI to form an Ero1-PDI 
mixed disulfide form. If the disulfide bond in the protein substrate is incorrectly 
formed, PDI catalyzes the reduction of these disulfide bonds and, subsequently, re-
oxidizes the protein substrate to form the native disulfide bond. Thus, as a general 
rule, cytoplasmic proteins contain free thiols, while proteins in other compartments 
such as the ER can possess disulfide bonds. An exception to this rule is a family of 
thermophilic organisms which has been discovered to produce intracellular proteins 
with disulfide bonds. This is presumably due to the presence of protein disulfide 
oxidoreductase (PDO) in their cytoplasm, which oxidizes the cysteines to disulfides 
within intracellular proteins.22 
In bacterial cells, the oxidative folding machinery parallels the machinery in 
mammalian cells, and the oxidation reaction is catalyzed by the enzymes DsbA, 
DsbB, DsbC and DsbD.17 The disulfide bond A (DsbA) enzyme oxidizes thiol groups 
of the substrate protein to a disulfide bond in the periplasm with the simultaneous 
reduction of its own disulfide bond. Then, the reduced DsbA is reoxidized by DsbB. 
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The oxidized state of DsbB is maintained by transferring electrons to ubiquinones 
(benzoquinone derivatives) and menaquinones (naphthoquinone derivatives), 
components of the respiratory electron transport chain system. When the substrate 
protein forms a non-native disulfide bond, DsbC enzyme reduces the non-native 
disulfides. This is followed by the subsequent re-oxidation of the substrate to form the 
native disulfide by DsbA or DsbC. Finally, DsbD functions to keep DsbC in the 
reduced state, and the oxidized DsbD can be reduced by cytoplasmic thioredoxin.  
 
1.3. Pathways of oxidative folding of proteins for disulfide formation 
Prior to the formation of a disulfide bond, the protein may or may not be folded 
into a native-like structure with the Cys residues in a favorable position to form a 
disulfide bond.23,24 In the case of bovine pancreatic trypsin inhibitor (BPTI), the 
formation of all three disulfide bonds in BPTI occurs via stable intermediates with a 
native conformation containing one or two native disulfide bonds.23,24 No significant 
amount of non-native disulfide intermediates was observed. However, the formation 
of only native-like intermediates does not always predominate; for example, hirudin, 
with three disulfide bonds, undergoes oxidative folding via heterogeneous 
intermediates with two or three non-native disulfide bonds.25 These scrambled 
disulfide bonds undergo reduction followed by oxidative rearrangement to form the 
native protein structure. The reductive unfolding of this protein follows a pathway 
similar to that of the folding process, but in reverse. The in vitro oxidative folding of 
human macrophage colony stimulating factor β (rhm-CSFβ) follows a pathway 
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similar to that of hirudin. The rhm-CSFβ protein is a dimer with three intermolecular 
disulfide bonds between the two monomers. Each monomer also contains three 
intramolecular disulfide bonds.26 The oxidative folding of rhm-CSFβ involves the 
formation of monomeric isomers with native and non-native intramolecular disulfide 
bonds; the monomer isomerization step is the rate-determining step in this process.26  
Upon disulfide shuffling, the protein forms a stable dimeric intermediate that 
possesses all of the intramolecular disulfides, including a non-native intermolecular 
disulfide bond. Rearrangement of the non-native disulfide bond creates the native 
oxidized rhm-CSFβ. 
Although the oxidative folding of different proteins may take different pathways, 
the process normally adheres to some general rules. Disulfide bond formation is 
usually favored at basic pH, and the presence of an oxidizing agent such as oxidized 
glutathione increases the rate of oxidative folding, whereas the presence of 
denaturants such as urea or guanidine hydrochloride (Gdn.HCl) hampers the folding 
process. These rules do not apply, however, to the oxidative folding of murine prion 
protein (mPrP 23–231), which has only one intramolecular disulfide bond at Cys179–
Cys214.27 The formation of a disulfide bond in reduced mPrP is very slow at pH 8.0 
in the absence of denaturant, but mPrP refolds properly in the presence of a 
denaturant and glutathione at pH 8.0.27 Contrary to intuition, the best pH condition to 
form a disulfide in mPrP is 4–5. This observation can be explained by the fact that, at 
alkaline and neutral pH, the reduced and unfolded mPrP is present in a stable 
intermediate conformation with its Cys residues buried and separated from each 
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other. The addition of glutathione, therefore, does not facilitate oxidation of Cys. The 
addition of denaturant and a pH of 4.0 facilitate the unfolding of the stable 
intermediate, bringing the two Cys residues closer and allowing them to form a 
disulfide bond. 
 
1.4. Effects of disulfide bond on protein stability   
Intramolecular disulfide bonds are known to contribute to protein thermal 
stability. Reducing all five disulfide bonds inactivates the Aspergillus niger phytase 
due to conformational change and/or unfolding.28 Another example of the effect of 
disulfide bonds on stability is observed in the soybean Bowman-Birk inhibitor (BBI). 
The crystal structure of BBI has a bow-tie motif, with a trypsin-binding loop at one 
end and a chymotrypsin-binding loop at the other. In contrast to most globular 
proteins, it has exposed hydrophobic patches and charged residues containing bound 
water molecules in its interior.29,30 Interestingly, BBI is remarkably stable against heat 
and chemical denaturants; this stability can be attributed to the seven intramolecular 
disulfide bonds within the protein’s structure that “lock” it in its native 
conformation.29  
Introduction of a disulfide bond by Cys mutation has been shown to improve the 
physical stability of some proteins. In case of Subtilisin E, mutations of Gly61Cys 
and Ser98Cys followed by the formation of the Cys61–Cys98 disulfide produce an 
active enzyme with a 4.5 °C increase in melting temperature and a half-life three 
times longer than that of the native protein.31 In addition, there was no change in its 
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enzymatic activity due to the engineered disulfide bond. Similarly, a Cys39–Cys85 
disulfide bond was engineered into dihydrofolate reductase (DHFR) without a 
significant alteration in its conformation. The disulfide mutant had an improved 
stability with  its ΔG° higher than that of the native protein by 1.8 kcal/mol.32 
At this point, it is necessary to discuss the thermodynamics behind the stabilizing 
effect of disulfide bonds on proteins. This stabilizing effect of disulfides is manifested 
by an increase in the melting point of the protein. The melting or unfolding transition 
of a protein is generally regarded as a reversible process between the native and the 
unfolded states. Differential scanning calorimetry (DSC) is usually employed to 
determine the reversible thermal unfolding of a protein. Superimposable DSC 
themorgrams resulting from repeated scans of the same protein sample imply a two-
state reversible unfolding process, which is depicted as , where N 
represents the native state and U, the unfolded state of the protein. This is also known 
as the “all or none” transition in statistical thermodynamics. In such a transition, the 
protein is either in the N state, with all its residues in the native (n) conformation or it 
is in the U state, where all its residues are in the unfolded (u) conformation. The 
Gibbs free energy for this process is related to the equilibrium constant of this 
reaction by the following equation: ΔG = –RT ln Keq. Keq is the ratio of the folding 
(kf) and unfolding (ku) rate constants. So, Keq = kf/ku. When a disulfide bond is 
introduced into a protein, there is likely to be a significant increase in the free energy 
of U. The transition state (TS) can either (i) have a large increase in its free energy 
similar to the unfolded state, in which case, the disulfide bond is lost in the TS or (ii) 
N U 
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have a negligible change in its free energy, in this case, TS is more N-like and retains 
the disulfide bond.33 In (i), the folding rate does not change much, but the unfolding 
rate decreases significantly. In (ii), the folding rate increases while the unfolding rate 
remains constant. In either case, the ratio of kf/ku, which is equal to Keq, decreases, 
leading to an increase in the free energy (ΔG) of the protein and making it 
conformationally more stable. The assumption is that there is little or no difference in 
the enthalpies (ΔH) of the disulfide-containing and reduced protein conformations. It 
has been proposed that the decrease in the entropy of U can be predicted with the help 
of the following equation: ΔS = –2.1 – (3/2)R ln n, where  n is the number of residues 
in the loop formed by the intramolecular disulfide bond.34 Similarly, reduction of 
disulfide bonds or mutation of disulfide-forming Cys residues in a protein can result 
in increased entropy of U. Consequently, Keq increases and ΔG of the protein 
decreases. This characteristic was observed in the 110 residue starch-binding domain 
of Aspergillus niger glucoamylase. The wild-type protein (SBD) possesses a disulfide 
bond between C3 and C98, creating a 94 residue loop between its N-terminus and the 
short loop between its seventh and eighth β-strands. Two different mutants 
C3G/C98G (GG) and C3S/C98S (SS) were constructed and their stability compared 
to that of SBD by determining their unfolding temperature and other thermodynamic 
parameters using DSC and CD techniques.35 The unfolding temperatures were 10 °C 
lower for the mutants (43 °C) compared to wild-type SBD (53 °C). The unfolding 
processes for SBD, GG and SS were determined to be reversible with GG and SS 
having a free energy lower than SBD by about 10 kJ/mol. The contribution from 
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entropic destabilization was much larger compared to that of the enthalpic 
destabilization.  
When multiple disulfide bonds are introduced into a protein, they can act 
cooperatively to stabilize the protein. The overall increase in the free energy of a 
protein in that case is higher than the sum of the increases in free energies due to 
individual disulfide pairs. This phenomenon is observed in the Bacillus circulans 
xylanase. When disulfide bonds were introduced into it by the following mutations: 
S110C/N148C (DS1) and A1GC/G187,C188 (cX1), the overall increase in its free 
energy was 5.4 kcal/mol, which is higher than the sum of the free energy increases 
(4.6 kcal/mol) due to each separate mutation by 0.8 kcal/mol. Consequently, the 
melting temperature of this double mutant was 12.4 °C higher than the native protein, 
compared to the 5.0 °C and 3.8 °C increase in melting points in the DS1 and cX1 
mutants.36  
It is difficult to predict whether increasing conformational rigidity upon addition 
of a disulfide bond will always improve the stability and/or activity of a protein. A 
good example that illustrates the effect of the location of a disulfide on structural 
stability and enzymatic activity was shown in T4 lysozyme. Four mutants of T4 
lysozyme with a disulfide bond at Cys9–Cys164, Cys21–Cys142, Cys90–Cys122, 
and Cys127–Cys154 were designed based on molecular modeling experiments.37 The 
thermal stabilities of the oxidized mutants were compared to their corresponding 
reduced mutants as well as to wild-type T4 lysozyme. The oxidized Cys9–Cys164 
mutant has a melting temperature 6.4 °C higher than that of the wild type while 
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maintaining its enzymatic activity. In contrast, the Cys21–Cys142 mutant has the best 
thermal stability but has no enzymatic activity. Finally, the Cys90–Cys122 and 
Cys127–Cys154 mutants have lower thermal stabilities and enzymatic activities 
compared to that of the wild-type enzyme. In another case, Ser52, Ser53, Ser78, 
Ser79, and Ser80 in alkaline phosphatase (AP) were mutated to the respective Cys 
residue; a disulfide bond was formed between the new Cys residue and Cys67. All of 
the disulfide mutants had improved thermal stability but lower enzymatic activities 
than that of the native AP.38 The decreased enzymatic activity of the mutant appeared 
to be due to the enhanced rigidity and lower substrate affinity of the active site 
imposed by the disulfide bond, which is located near the residues. Thus, the location 
of the non-native disulfide bond affects the physicochemical stability and biological 
properties of the mutant proteins in a manner difficult to predict.  
To impose conformational rigidity, a disulfide bond also has been introduced in 
peptides to form cyclic structures (cyclic peptides), which stabilizes specific 
secondary structures (i.e., β- and γ-turns). The formation of cyclic peptides in some 
cases enhances  receptor-binding affinity and selectivity, as shown in opioid 
peptides.39 Several cyclic peptides with a disulfide bond have been marketed as 
therapeutic agents, including Integrilin®40,41 and oxytocin (Pitocin®).42 Integrilin® is 
a cyclic Arg-Gly-Asp (RGD) peptide, which is used to treat thrombosis; it binds 
selectively to gpIIb/IIa receptors on the surface of platelets, thus blocking fibrinogen-
mediated platelet aggregation.40,41 Cyclic peptides also have been shown to be  more 
stable to chemical and enzymatic degradation than their parent linear analogues. The 
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Asp-mediated chemical degradation of RGD peptides was suppressed by the 
formation of a cyclic RGD peptide with a disufide bond; thus, the chemical stability 
of the cyclic RGD peptide is higher than that of the parent linear form.43-45 
Earlier, we discussed the role of disulfide bonds in improving protein stability. 
Disulfides have also been found to improve stability of antibodies. Introduction of 
non-native disulfide bonds, however, can also lead to a decreased protein stability. 
Such is the case with SBD. Previousy, we described the increase in stability of SBD 
by the creation its two mutants: GG and SS. When two new mutants, C3S and C3G 
were created, they both showed a 9 °C decrease in the melting point of wild-type 
SBD. The explanation for this decreased stability was that the remaining unmutated 
C98 of SBD was able to form disulfide dimers in the native state.46 Thus, disulfide 
bonds can have a favorable or an unfavorable effect on protein stability. 
 
1.5. Analysis of free thiols and disulfide bonds 
The presence of a free thiol group in the Cys residues in a protein can be 
quantitatively determined by different methods, including the use of maleimide (i.e., 
ThioGlo),47 Ellman’s reagent (5,5'-dithiobis-(2-nitrobenzoic acid) or DTNB),48-51 and 
bimane reagents (Figures 1.2a and 1.2b).52,53 The presence of a disulfide bond can be 
detected using the crabescein reagent.54 Ellman’s reagent (DTNB) was the earliest 
reagent widely used for estimating the number of thiol groups. The reaction between 
DTNB and thiol group(s) produces an equivalent amount of 5-thio-2-nitrobenzoic 
acid, the absorbance of which can be measured at 412 nm. It was found that the 
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DTNB method may underestimate the concentration of thiol groups in a protein due 
to its incomplete reaction.47,55 Addition of cytamine as an accelerator of the DNTB-
thiol reaction improves the accuracy of thiol determination (Figure 1.2a).51 As an 
alternative reagent, 4,4'-dithiodipyridine (DTDP) has a performance similar to that of 
the DTNB/cystamine in determining thiol concentrations (Figure 1.2a).51 Upon 
reaction with the thiol group, DTDP releases 4-thiopyridine (4-TP), which absorbs at 
342 nm. One drawback to using DTDP is that some proteins have inherent 
absorbance at 342 nm (due to the ligand metal charge transfer band during the 
chelation of thiol groups with some metals from the f-block of the periodic table), 
which can interfere with the quantitative measurement of 4-TP. A new derivative of 
Ellman’s reagent, n-octyl-5-dithio-2-nitrobenzoic acid (ODNB) has been designed; 
this reagent can react with all thiol groups of a protein, including the buried ones (as 
it is more hydrophobic than DTNB), in a relatively short time (Figure 1.2a).55 
Maleimide derivatives are also used to determine the number of thiol groups in a 
protein. ThioGlo® reagents (ThioGlo®1, λEx= 379 nm and λEm = 513 nm) are 
maleimide derivatives of naphthopyranone fluorophores that emit fluorescence upon 
thiol alkylation (Figure 1.2a). ThioGlo®1 is forty times more sensitive than DTNB 
and other maleimide reagents. The protein-ThioGlo adduct does not require 
separation prior to quantitative determination due to the low fluorescence of the 
starting reagent. One caution is that the reaction should not be carried out at a higher 
pH (>8) because of the possibility of amine alkylation of the maleimide and adduct 
degradation. Possible disadvantages include the low water solubility of the ThioGlo  
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Figure 1.2a: Various labeling reagents for the detection and quantification of protein 
thiols and disulfides: 5,5'-dithio-bis(2-nitrobenzoic acid) (DTNB or Ellman’s 
reagent), 4,4'-dithiodipyridine (DTDP), n-octyl-5-dithio-2-nitrobenzoic acid (ODNB), 
and ThioGlo®1. 
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Figure 1.2b: Labeling cellular protein thiols with bimanes: monobromobimane 
(mBBr) and dibromobimane (bBBr) label thiols inside cells as well as on cell 
surfaces, whereas monobromotrimethylammoniobimane (qBBr) labels only the cell 
surface protein thiols. 
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reagent and the instability of protein-ThioGlo adducts, which may lead to inaccuracy 
in the quantitative determination of the thiol group. 
Bimane derivatives (i.e., monobromobimane (mBBr), dibromobimane (bBBr) and 
monobromotrimethylammoniobimane (qBBr)) also have been developed for 
quantitative determination of thiol groups of cellular proteins (Figure 1.2b). Bimane  
derivatives have no intrinsic fluorescence; upon reaction with thiol groups in proteins, 
they become highly fluorescent.52 Both mBBr and bBBr can be used to measure the 
total cellular thiol content and qBBr can be used to measure the extracellular and 
membrane thiol content. Due to the presence of a charged group in qBBr, this 
molecule cannot permeate cell membranes, and it, therefore, may be used to measure 
selectively the extracellular thiols. mBBr can penetrate cell membranes and react with 
thiols in the cells as well as the thiols in the extracellular space. Thus, the difference 
in the thiol content measured by mBBr and qBBr gives the amount of thiols inside the 
cells. One of the advantages of using these bimane derivatives is that they are stable 
during exposure to air and irradiation as well as during general laboratory procedures. 
Bimane has also been used to determine the intracellular levels of thioredoxin after 
isolating the modified protein using an antibody affinity Sepharose column. After 
elution from the column, the amount of thioredoxin can be determined using a 
fluorescence spectrometer.56 
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1.6. Degradation of disulfide bonds 
Chemical degradation of disulfide bonds has been studied in both peptides and 
proteins with most of the disulfide bond degradation observed under neutral and basic 
conditions (Figures 1.3a, 1.3b and 1.3c).43,57 Degradation of disulfide bonds can be 
classified into three major pathways: (1) direct attack on the sulfur atom by the 
hydroxyl anion, opening the disulfide bond to form sulfenic acid/thiolate anion 
(Figure 1.3a); (2) A β-elimination reaction in which the α-proton of the Cys residue is 
abstracted (which produces dehydroalanine/persulfide (Figure 1.3b)); and (3) the α-
elimination caused by the hydroxyl ion attacking the β-proton of the Cys residue to 
produce the thiolate/thioaldehyde (Figure 1.3c).58  
The hydroxyl attack of the disulfide bond produces sufenic acid and thiolate anion 
(1, Figure 1.3a). The thiolate anion 1 can proceed to attack another disulfide bond on 
another protein molecule to produce a thiolate dimer intermediate 2 (pathway a, 
Figure 1.3a). This intermediate (2) undergoes three possible reactions as shown in 
pathways b, c, and d. In pathway b, intramolecular nucleophilic attack of the sulfenic 
acid by the thiolate anion produces dimer 3 with two intermolecular disulfide bonds. 
Intermediate 2 can form sulfenic acid dimer 4 by abstracting a proton from water 
(pathway c). Higher molecular weight oligomers such as trimer 5 can be produced via 
intermolecular disulfide bond reactions utilizing pathway d. The thiolate anion 1 can 
also undergo an intermolecular reaction between the sulfur atom of the sufinic acid 
group and a disulfide in another molecule to give an intermediate dimer 6 as shown in  
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Figure 1.3a: Degradation reactions of protein disulfide bonds in neutral and basic 
conditions that involve a direct attack on the sulfur atom by hydroxyl anions. 
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Figure 1.3b: Degradation reactions of protein disulfide bonds in neutral and basic 
conditions involving a β-elimination reaction. The α-proton of the Cys residue is 
abstracted by the hydroxyl anion. 
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Figure 1.3c: Degradation reactions of protein disulfide bonds in neutral and basic 
conditions involving α-elimination reaction. The β-proton of the Cys residue is 
abstracted by the hydroxyl anion to produce a thiolate/thioaldehyde (15). 
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pathway e. The resulting thiolate 6 oligomerizes by reacting with another protein 
molecule to generate a trimer 7 (pathway f); further intermolecular reactions lead to 
higher molecular weight oligomers. Intermediate 6 also can form a dimer molecule 
with two free thiols (8).   
The second degradation pathway is via β-elimination through the hydroxyl anion 
abstraction of the acidic Cα proton of Cys residue to yield a dehydroalanine-
persulfide 9 (Figure 1.3b). The disulfide bond can be reconnected by nucleophilic 
attack on the dehydroalanine by the persulfide anion (pathway a, Figure 1.3b). 
Theresulting products (10) form a racemic mixture at the Cα of Cys residue (10, 
Figure 1.3b). The persulfide 9 can undergo a sulfur extrusion reaction via pathway b 
to yield the thiolate anion 11. The thiolate anion in 11 reacts with the alkene 
functional group of the dehydroalanine to generate the thioether 12; this reaction can 
also take place in an intermolecular fashion to produce oligomers. A similar reaction 
has been observed in an IgG1 monoclonal antibody59 and cyclic peptides containing a 
disulfide bond.43,57  In the IgG1, this thioether bond was observed at C233, which 
links the heavy chain to the light chain.59 This modification was identified by LC-MS 
tandem mass spectrometry. Abstraction of a proton from the solvent by the thiolate 
anion 11 produces dehydroalanine-thiol 13. There is a possibility that the amino 
group from either the Lys or the N-terminus of the protein may react with the alkene 
group of the dehydroalanine to produce a secondary amine 14. This reaction has been 
observed as a degradation product of cyclic peptides.43,57 
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Finally, the α-elimination reaction proceeds via the abstraction of the β-proton of 
the Cys residue followed by disulfide bond breakage to produce thiolate/thioaldehyde 
15 (Figure 1.3c). Protonation of the thiolate anion yields thiol-aldehyde 16 (pathway 
a). In the presence of the hydroxyl anion, the thioaldehyde group can be converted to 
an aldehyde 18 via intermediate 17 (pathway b). An amino group (i.e., Lys or N-
terminus) that is in close proximity to the aldehyde group in 18 may also produce an 
imine product 19. The imine reaction may produce bimolecular reactions to create 
oligomers. 
Intermolecular covalent bond reactions (disulfide, thioether, amine and imine in 
Figures 1.3a, 1.3b and 1.3c) producing oligomers can lead to the association, 
aggregation and precipitation of proteins.  For example, intermolecular disulfide 
formation causes aggregation of nascent thyroglobulin (Tg) protein. Monomeric Tg is 
a precursor to the synthesis of thyroid hormone. It contains more than 100 Cys 
residues and can produce aggregates through the formation of non-native 
intermolecular disulfide bonds due to the oxidizing environment in the endoplasmic 
reticulum of thyroid cells.60  During the transport of Tg to the golgi complex, the 
aggregates of Tg undergo disulfide reduction and dissociation to form monomers with 
assistance from molecular chaperones. This suggests that the incidence of Cys 
residues in the protein as well as the redox status of its environment are important 
factors that contribute to its disulfide-mediated aggregation. Intermolecular disulfide 
bond reactions in α- and β-crystallin induced by X-ray irradiation were shown to be 
partly responsible for cataract formation in the rabbit eye lens. It is interesting to note 
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that the reaction between prednisolone and the amino group(s) of crystallin alters 
crystallin conformation to expose the buried thiol groups.61,62 These exposed thiol 
groups then undergo oxidation to form intermolecular disulfides, which cause protein 
aggregation and precipitation.61 It was made clear in a subsequent study that the 
crystallin that underwent conformation change on reaction with predisolone was α-
crystallin.63 In most cases, the disulfide bond can be reversed by reducing agents (i.e., 
DTT). Intermolecular disulfide bond formation has been suggested to induce the 
aggregation of BSA. DTT has been shown to suppress the aggregation of BSA.64 
 
1.7. Chemical modification of Cys thiols of proteins 
The thiol group in Cys can undergo oxidation reactions to form sulfenic (R-S-
OH), sulfinic (R-SO2H), and sulfonic (R-SO3H) derivatives as well as the disulfide 
bond. Thiol groups are one of the most reactive groups in proteins and can participate 
in side reactions with reagents used to manipulate other functional groups in a protein 
and the other solution components. The presence of a free cysteine residue may cause 
unwanted intramolecular disulfide scrambling, and covalent oligomerization via 
intermolecular disulfide formation. To prevent these reactions, thiol groups can be 
derivatized with acetate, acetamide, 1,3-propane sultone65, methyl 
methanethiosulfonate, methoxycarbonylmethyl disulfide66, maleimide, tetrathionates, 
and dinitrophenyl alkyl disulfides (DNPSSR)67 (Figure 1.4). Human serum albumin, 
[Lys8] vasopressin, bovine insulin, and bovine pancreatic ribonuclease have been 
alkylated with 1,3-propane sultone to increase their solubility and stability to acid  
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Figure 1.4: Some of the reagents used for the modification of free thiols in proteins. 
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hydrolysis. Alkylating the free thiol of the tetanus toxoid with N-ethylmaleimide 
inhibits moisture-induced aggregation of the lyophilized toxoid.68 
To avoid side reactions of the Cys thiol group, Cys has frequently been mutated to 
Gly, Ala, and Ser residues in proteins.  The C6A, C111S and C6S/C111A mutants of  
human CuZn dismutase (SOD) and the C6A mutant of bovine SOD showed greater 
resistance to loss of enzymatic activity than did the respective native SODs upon 
thermal unfolding at 70 °C.69 This corresponds to the fact that the mutants can 
reversibly refold after denaturation while the unfolded native SOD refolds 
incorrectly. Cys mutation studies have been used to determine the role of free and 
disulfide-bonded Cys residues in the function of many proteins. Meprins, cell surface 
and secreted metalloendopeptidases, are oligomers made up of disulfide-linked 
multidomain subunits. 
Mutations of C320A and C289A of mouse meprin-α both resulted in an increased 
susceptibility to proteolytic degradation and heat deactivation. Although the mutants 
retained their catalytic activity toward a bradykinin peptide, they displayed decreased 
activity toward the protein substrate azocasein. It was found that the C320A mutant 
only formed monomers, while the C289A mutant formed dimers and oligomers, 
suggesting that Cys 320 but not C289 may be involved in inter-subunit disulfide 
formation.70 Mutation of either Cys residue resulted in a change in protein structure 
causing it to lose its enzymatic activity toward a protein substrate. Thus, Cys 
mutation is a technique that may not only shed light on the importance of the state of 
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Cys residues (paired or reduced, intra- or interprotein pairing) in a particular protein 
but also may help to distinguish the different roles of each Cys in the protein. 
Cys residues of therapeutic proteins also have been PEGylated to improve their 
physicochemical stability, pharmacokinetics and pharmacodynamics properties. 
PEGylated proteins usually have reduced glomerular filtration and immunogenicity. 
The molecular weight of these PEG reagents can range from 2 to 50 kDa. Since 
proteins generally contain fewer unpaired Cys residues compared to Lys residues, the 
PEGylation of a Cys residue is more selective than PEGylation of Lys residue. 
PEGylation of Lys residues gives a heterogenous mixture of products with a 
distribution of conjugated products, which is difficult to control. The site-specific 
PEGylation of the Cys residue is normally carried out with PEG-maleimide, PEG-
acrylamide, PEG-acrylate, PEG-vinyl sulfone, PEG-epoxide or PEG-iodoacetamide. 
In a protein without a free thiol, a surface residue away from the active site can be 
mutated to a Cys residue followed by PEGylation. This method has been successfully 
used to improve the half-life of granulocyte colony stimulating factor (G-CSF)71 and 
the Q5C analog of interferon-α (IFN-α)72, immunotoxin anti-Tac(Fv)-PE38 (LMB2), 
73 and Eryhtropoietin (EPO).74  When LMB2 was stabilized by PEGylation using 5– 
or 20– kDa PEG-maleimide, there was an increase in plasma stability (five- to eight- 
fold) and antitumor activity (three- to four- fold).73 In this case, LMB2’s animal 
toxicity and immunogenecity were significantly lower than that of the parent toxin. A 
native disulfide bond can also be conjugated with PEG by reaction with PEG-
monosulfone; the product forms a three carbon bridge with the two sulfur atoms from 
 29
the native disulfide bond. Interferon α-2b, anti-CD4+ antibody, and L-asparaginase 
also have been PEGylated in this manner.75 In the case of interferon α-2b, the 
PEGylated product maintains its biological activity as well as its tertiary structure.76 
For an in-depth discussion of PEGylation, the readers are directed towards two 
excellent reviews published recently.77,78 
 
1.8. Conclusions 
Thiol groups and disulfides have important roles in the stability and solubility of 
proteins. Thiols and disulfides are two of the most reactive groups in proteins. 
Increased research is being devoted to studying the role of thiols and disulfides in 
problems associated with protein molecules. Studies have shown some disulfide 
bonds in proteins to be essential for either protein stability and/or activity. On the 
other hand, some non-native disulfide bonds in proteins are a result of altered in vitro 
or in vivo conditions and are detrimental to protein stability and/or activity. Various 
reagents have been designed to detect and quantify free thiols and disulfides in 
proteins. The choice of the appropriate labeling agent should be made after careful 
consideration because they all have advantages and disadvantages. Changes in native 
thiol and/or disulfide content in proteins can be blocked by either the addition of 
appropriate redox reagents or irreversible conjugation with various agents as 
described above. Mutation of the Cys residue to another amino acid (i.e., Ser, Ala) is 
an alternative strategy when the residue is not essential to protein activity. Protein 
molecules are highly complex systems. Knowledge of the role of Cys residues in 
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these macromolecular systems is continuously expanding. It is hoped that the growing 
appreciation for the role of thiols and disulfides in protein structure may lead to new 
methods to improve the success in formulating proteins as therapeutic agents. 
 
1.9. Application of the information above to current work 
As mentioned earlier, EC1 forms disulfide-linked dimers; these dimers form 
physical oligomers. This heterogenous nature of EC1 in solution is undesirable during 
the study of its biological activity assay. In the current work, we examine the effect of 
intermolecular disulfide formation on the stability of EC1. We also apply various 
methods to block the formation of disulfide-linked dimers. In Chapter 2, we employ 
the simple addition of DTT to maintain EC1 in its monomeric form and compare the 
stability of EC1 in the absence and presence of DTT. In Chapter 3, we eliminate the 
need to add reducing agents such as DTT to EC1 solution to maintain EC1 in 
monomeric form by alkylating its Cys thiol group with iodoacetamide. We study the 
stability of the alkylated EC1 and compare it with that of unmodified EC1. In Chapter 
4, we modify the Cys thiol group of EC1 by its reaction with maleimide-activated 
polyethylene glycol (PEG). PEGylation of EC1 in this manner is expected to prevent 
intermolecular disulfide formation; it also is expected to decrease hydrophobic 
interactions between EC1 molecules by attracting water molecules to the protein 
surface and forming a hydrophilic shell. We study the stability of the PEGylated EC1 
and again, compare it with that of the unmodifed EC1. We also compare the 
secondary and tertiary structures of both, the alkylated derivative as well as the 
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PEGylated derivative with those of unmodified EC1. Retention of the secondary 
structure after alkylation or PEGylation is expected to be important for the retention 
of the biological activity of EC1. 
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Chapter 2 
The effect of covalent dimerization on the structure and stability  
of EC1 domain of human E-cadherin 
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2.1. Introduction 
The EC1 domain of cadherins has been shown to be important for the homophilic 
selectivity of cadherins.1-7 E-cadherin, a member of this cadherin family, is a 
transcellular protein located in the adherens junctions of epithelial and endothelial 
tissues. It creates a paracellular barrier to transepithelial transport of large molecules 
through homophilic interactions on the lateral surface of same cell surface as well as 
opposing cell surfaces. Two E-cadherin molecules from the same cell surface form a 
cis-dimer through interaction of their extracellular segments; interaction of cis-dimers 
from opposing cell surfaces forms trans-oligomers. It has been proposed that the 
formation of cis-dimers of E-cadherin is necessary for the formation of trans-
oligomers.3,4  The extracellular portion of E-cadherin is composed of five sub-
domains EC1 through EC5. Each of these sub-domains has an immunoglobulin-like 
β-sheet-rich structure. All five sub-domains as well as the linker sequences between 
the sub-domains possess Ca2+ binding residues. Ca2+ binding has been shown to be 
essential for E-cadherin mediated cell adhesion. The EC1 domain is the N-terminal 
domain and is located farthest from the cell surface. The EC1 domain has been shown 
to interact with an EC1 domain of a neighboring E-cadherin molecule to form cell-
cell adhesion sub-structures in the intercellular junctions. E-cadherin-mediated 
homophilic cell-cell adhesion can be inhibited by EC1-derived peptides,8,9 These 
peptides temporarily open the intercellular junctions of MDCK monolayers to 
enhance the transport of 14C-mannitol.10,11 Although the EC1 domain can modulate 
the E-cadherin-mediated Caco-2 single cell adhesion to modified Caco-2 cell 
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monolayers, it is difficult to store this molecule in solution due to its instability as 
described below. Thus, it is of interest to study the stability of the EC1 domain so that 
its behavior can be better understood and it can be stabilized for future studies.  
The recombinantly expressed EC1 domain in this study is from human E-
cadherin. It contains 105 amino acid residues (MW = 11,628 Da), including four 
additional non-native amino acids (GSHM) at the N-terminus. The Cys9 residue in 
the native EC1 is located at Cys13 in the EC1 domain studied here (Figure 1a).12 The 
monomeric form of the EC1 domain can readily form a covalent dimer via 
intermolecular disulfide bond formation of the Cys13 residues followed by the 
formation of physical oligomers as well as precipitates.13 The dimeric and oligomeric 
forms cannot be directly used to study the biological activity of the EC1. We propose 
that the formation of physical oligomers is induced by the presence of a covalent 
dimer; thus, blocking the formation of the covalent dimer may inhibit the 
oligomerization and precipitation of the EC1 domain. Therefore, the goal of this study 
was to investigate the effect of covalent dimerization as it pertains to oligomerization, 
precipitation and the chemical stability of EC1. Stabilization of the monomer should 
help our effort in (a) elucidating the mechanism of interaction between the EC1 
domain and other recombinantly expressed domains (EC2, EC3, EC4, and EC5) of E-
cadherin, (b) evaluating the activity of the EC1 domain in blocking homotypic and 
heterotypic cell-cell adhesion, and (c) determining the binding site(s) of E-cadherin 
peptides on the EC1 domain. Furthermore, EC1 can also provide a general model for 
studying the oligomerization process of a protein in solution.  
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Figure 2.1a: Primary sequence of the EC1 protein obtained at the end of the 
purification process. The first four residues GSHM are non-native residues that result 
from the type of vector used for transformation into E. coli cells. The single Cys13 
residue is equivalent to Cys9 residue in the native EC1. The potential hydrolysis site 
is also indicated. 
 
 
 
 
 
 
 
 47
In this work, we studied the accelerated solution physical and chemical stability 
of the EC1 domain at different temperatures and pH values in the absence and 
presence of dithiothreitol (DTT). The chemical degradation process was evaluated by 
high pressure liquid chromatography (HPLC) and mass spectrometry (MS). The 
physical stability and structural properties of the EC1 domain were evaluated using 
spectroscopic methods (i.e., CD and fluorescence). The effect of pH and incubation 
time on the secondary structure was studied by performing CD spectroscopy. Intrinsic 
fluorescence emission studies also were conducted to follow changes in the tertiary 
structure of EC1 upon incubation under different conditions. Molecular dynamics 
simulations were used to investigate the dynamic properties of the EC1 monomer and 
dimer; these simulations suggest that the EC1 dimer may undergo conformational 
changes more readily than the monomer. The results also indicate that the formation 
of the intermolecular disulfide bond by EC1 is unfavorable to its physical and 
chemical stability.  
 
2.2. Materials and methods 
2.2.1. Expression of EC1:  
The DNA of EC1 was produced by performing a polymerase chain reaction 
(PCR) of the cDNA of human E-cadherin (obtained from David Rimm, M.D., Ph.D., 
Yale University School of Medicine).  The nucleotide sequence 5'-
GTAGCATATGGACTGGGTTATTCCTC-3' was used as the forward primer and 5'-
GAATCATATGTCACTGATCGGTTACCGTG-3' was used as the reverse primer. 
 48
The EC1 DNA thus amplified was then ligated into pET-15b vector (obtained from 
EMD Biosciences) using the restriction site Nde I. The pET-15b vector has a 
sequence that codes for an N-terminal His-tag (6 Histdine residues in a row) and 
allows us to use the metal binding property of this His-tag for eventual purification of 
the recombinantly expresed EC1. DNA sequencing was performed to confirm the 
ligation product contained EC1 sequence. The ligation product was then transformed 
into competent BL21 (DE3) E. coli cells (obtained from Novagen, Inc). These E. coli 
cells were grown in LB medium at 37 °C and 250 rpm shaking. When the optical 
density of the E. coli reached 0.5 units at 600 nm, the cells were induced with 
isopropyl-β-D-thiogalactopyranoside (IPTG). The cell growth was monitored until 
their UV absorbance at 600 nm reached a plateau (usually about 1.5 units after 3 h). 
The E. coli cells were then harvested by centrifugation at a speed of 10,000 x g for 6 
min. The pellets obtained were resuspended in a buffer containing 100 mM tris-
(hydroxymethyl)aminomethane (Tris), 100 mM NaCl, and 2.0 mM β-
mercaptoethanol (BME) at pH 8.0. The suspension of cells was passed through a 
French pressure cell at a pressure of more than 1000 psi to lyse the cells and release 
the expressed EC1 into the buffer.14 The lysed cell suspension was then centrifuged 
for 45 min at a speed of 48,000 x g at 4 °C to separate the insoluble cell debris from 
the dissolved EC1. The supernatant obtained in this manner was further cleared of 
any particulate matter by passage through a 0.45 micron filter. The EC1 obtained in 
this manner has a His-tag linked to its N-terminus with a sequence (LVPRGS) that is 
a substrate for Thrombin. The cleavage of the His-tag with Thrombin results in 
 49
retention of a four-amino acid extension (GSHM) preceding the EC1 protein. As 
such, the numbering is adjusted by +4 compared to human EC1. 
 
2.2.2. Purification of the EC1 Protein: 
The lysed cell suspension above containing His-tagged EC1 was loaded onto a 
HisTrap HP nickel affinity column (GE Healthcare).14 This was followed by elution 
with washing buffer containing 100 mM Tris and 100 mM NaCl at pH 8.0 with 
increasing concentration of imidazole (from 10 mM to 50 mM) to wash off other non-
specifically bound proteins. The EC1-Histag protein bound to the nickel affinity 
column was then eluted by increasing the concentration of imidazole to 150 mM. The 
eluted EC1-Histag was dialyzed against a buffer containing 20 mM Tris, 100 mM 
NaCl, and 10 mM EDTA at pH 8.0 to remove any residual nickel. The EC1-Histag 
solution was then dialyzed against buffer containing 20 mM Tris and 100 mM NaCl 
at pH 8.0 to remove the EDTA. The pure EC1-Histag was concentrated to 1.0 mL 
followed by dilution with 8 mL of deionized water. To 8.0 mL of diluted protein, 
thrombin (0.5 units/mg of EC1-Histag) was added in cleavage buffer (200 mM Tris, 
1.5 M NaCl, 25 mM CaCl2, 2 mM BME) and incubated with gentle shaking for 2 h at 
room temperature to cleave the Histag from the EC1 domain. At the end of 2 h 
incubation, the mixture was run through a benzamidine column to trap the thrombin; 
a mixture of EC1 and cleaved Histag was eluted from the column using buffer (20 
mM Tris, 100 mM NaCl, 2 mM BME) at pH 8.0. The eluted mixture was then passed 
through the nickel affinity column to separate the pure EC1 from the Histag. The pure 
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EC1 obtained was then dialyzed in a buffer containing 20 mM Tris, 100 mM NaCl, 2 
mM BME, and 10 mM EDTA at pH 8.0 to remove any residual nickel.  Finally, the 
EC1 solution was dialyzed against a buffer containing 20 mM Tris, 100 mM NaCl, 
and 2 mM BME at pH 8.0 to remove any remaining EDTA. SDS-PAGE of the 
protein was performed to confirm its purity, and the identity of EC1 was confirmed 
by determining its molecular weight with electrospray ionozation (ESI) positive mode 
time of flight (TOF) mass spectrometry (MS). The molecular weight of the 
recombinant EC1 determined was 11,628 amu which is the same as its theoretical 
molecular weight (Figure 1b). 
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Figure 2.1b: Mass spectrum of purified EC1 as obtained from electrospray ionization-
time-of-flight mass spectrometer (ESI-TOF MS). 
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2.2.3. Chemical Stability Studies: 
Chemical stability studies of 86 μM EC1 (1 mg/mL) were performed at pH 3.0, 
7.0, and 9.0 and temperatures of 4 °C, 37 °C, and 70 °C. The buffers used were 100 
mM phosphate for pH 3.0, 50 mM phosphate for pH 7.0, and 100 mM borate 
containing 0.08 M NaCl for pH 9.0. EC1 was dialyzed into each buffer using Amicon 
centrifugal filter devices containing a membrane with molecular weight cut-off of 
10,000 Da. Samples containing the EC1 protein at different pH values were incubated 
at 4 °C, 37 °C or 70 °C in the absence and presence of 0.1 M DTT. The molar ratio of 
DTT: EC1 in these studies is approximately 10,000:1. Hence, a 99.9% loss in the 
amount of DTT at 70 °C would be expected to still leave enough DTT to maintain 
EC1 in its reduced monomeric form. Three samples were drawn out at each time 
interval and immediately frozen at –70°C prior to analysis. Each of the frozen 
samples was thawed and centrifuged at 12,000 x g for 10 mins at 4 °C before HPLC 
analysis described below. 
The degradation profiles of the EC1 protein were evaluated using SDS PAGE and 
an HPLC system (Dynamax SD-200). Sample (25 μL) were injected onto an 
analytical HPLC column (C18, Varian Microsorb, pore-size 300Å, dimensions 250 x 
4.6 mm) followed by gradient elution at a rate of 1.0 mL/min. Solvent A (94.9% 
double distilled water, 5% acetonitrile (ACN) and 0.1% TFA) and solvent B (100% 
ACN) were used in various proportions for the separation and resolution of eluting 
peaks. The sequence of the gradient elution was as follows: 0% B to 45% B in 2.0 
min, 45% B to 51% B in 10.0 min, at 51% B for 5.0 min, 51% B to 100% B in 2.0 
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min, at 100% B for 2.0 min, and 100% B to 0% B in 1.0 min. The eluted protein and 
its degradation products were detected by a Varian Prostar UV detector at a 
wavelength of 220 nm. The degradation products were identified by LCMS 
employing a C4 micro-column with an ESI positive mode MS with TOF detection.  
 
2.2.4. Physical Stability Studies: 
Long-term physical stability studies of EC1 were performed at a concentration of 
86 μM (1.0 mg/mL) and pH 3.0, 7.0, and 9.0 under the same conditions as the 
chemical stability studies (see above). The sealed EC1 samples (300 μL in each vial) 
were stored at 4 °C for 14 or 28 days in the absence and presence of 2.0 mM DTT. 
The CD spectra of the samples prior to incubation (day 0) and after incubation were 
collected in the far-UV spectrum (200–250 nm) at 1 nm bandwidth and 0.1 cm 
pathlength using a Jasco spectropolarimeter (J–720) equipped with a Peltier 
temperature controller. The thermal unfolding profile of the protein samples was 
monitored in two ways: 1) by collecting CD spectra every 5 °C with increase in 
temperature from 10 °C to 65 °C at the rate of 15 °C per hour after equilibrating the 
sample for 300 s at each temperature and 2) by monitoring the CD signal at 218 nm 
(for change in β-sheet structure) at every 0.5 °C rise in temperature.15 Each sample 
was run in triplicate and a blank sample spectrum containing the buffer alone was 
subtracted from each sample spectrum. The ellipticity value at 218 nm was plotted for 
each temperature point to examine the thermal unfolding profile of the sample. This 
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plot was fitted to a sigmoidal function using Origin 7.0 software, and the midpoint of 
each plot was taken as the thermal unfolding (denaturation) temperature.  
For fluorescence spectroscopy studies, 1.0 ml 86 μM EC1 (1 mg/mL) was 
incubated at pH values of 3.0, 7.0 and 9.0 each for a period of 28 days at 4 °C. At 
days 0, 14, and 28, EC1 (0.3 mL) was withdrawn from the incubated samples and 
diluted to 0.1 mg/mL with buffer of the corresponding pH. This solution (0.9 mL) 
was loaded into a quartz fluorescence cuvette of 1 cm pathlength and intrinsic 
fluorescence spectra were collected on a PTI QuantaMaster spectrofluorometer at 
2.5 °C intervals from 10 °C to 87.5 °C. The analyte was equilibrated for 5 min at 
every temperature prior to the spectrum collection. An emission spectrum was 
obtained from 305 nm to 405 nm after excitation of the analyte at 295 nm (>95% Trp 
emission).16 The excitation and emission slits were adjusted so that the emission at its 
maximum was between 500,000 and 1,000,000 counts/sec. Each experiment was 
performed in triplicate, and the appropriate buffer was run as a control. 
The entire analysis described above was repeated in the presence of 2.0 mM DTT. 
To analyze the data, the signals from the blanks were subtracted from emission 
spectra of the samples. Each fluorescence emission spectrum obtained was fitted to an 
extreme assymetric peak function using the non-linear curve-fitting wizard of Origin 
7.0 software to obtain the wavelength of maximum emission. The wavelength of 
maximum emission at each temperature was plotted against temperature to calculate 
the transition temperature.  
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2.2.5. Computer Simulations and Molecular Modeling:  
Molecular dynamics simulations of the E-cadherin EC1 monomer (PDB code: 
1EDH)1,17 and the EC1 domain dimer containing a disulfide bond were performed for 
10 ns using Nanoscale Molecular Dynamics 2.6 (NAMD 2.6).18 Both systems 
were solvated by cubic boxes of TIP3P water with a margin of ~15 Å between the 
protein and the boundaries of the periodic box. The Na+ and Cl– counterions were 
added to neutralize the system. Protein, water, and ions were modeled with the 
CHARMM 22 force field.18 The particle mesh Ewald method was used to treat long-
range electrostatics interactions. Periodic boundary conditions, 10 Å cutoff, and a 
switching cutoff distance of 8 Å for nonbonded van der Waals (vdw) interactions 
were applied. All bonds involving hydrogen atoms were constrained using the 
SHAKE algorithm and a time-step of 2 fs was employed to integrate the equations of 
motion. The equilibration stage includes energy minimization of the protein for 5,000 
steps followed by minimization of the complete system for 10,000 steps to remove 
close contacts. Finally, the entire system was subjected to a gradual temperature 
increase from 0 K to 300 K in intervals over 30 ps by increasing the temperature 
of Langevin damping and Langevin piston by 30 K in each step. The complete system 
was then equilibrated for 300 ps. Pressure and temperature were maintained at 1 atm 
and 300 K using a Langevin barostat and Langevin thermostat.  
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2.3. Results 
2.3.1. Chemical Stability of EC1:  
The EC1 protein was incubated in the presence and absence of 0.1 M DTT at pH 
3.0, 7.0, and 9.0 at 4 °C, 37 °C, and 70 °C. Samples were drawn out at 0.5, 1, 2 and 4 
h time-points and the supernatant after centrifugation of each sample at 12,000 Χ g 
was injected into HPLC system. The decrease in the area under the EC1 peak as well 
as the increase in the area under any new peaks, if present, was monitored.  
Degradation products, represented by new peaks, were identified using LCMS (ESI-
TOF). Potential products include deamidation and peptide bond hydrolysis products. 
The results of this study are described below. 
Stability at 4 °C: When incubated at 4 °C for 4 h at pH values of 3.0, 7.0, and 9.0, 
there was no substantial decrease in the amount of EC1 protein as detected by the 
HPLC analysis described before (data not shown). There was no observable 
difference in the stability of EC1 in the absence and presence of DTT, suggesting that 
the protein was stable at low temperature.  
Stability at 37 °C: The EC1 protein was stable at pH 3.0 for 4 h at 37 °C, and it 
was difficult to distinguish the effect of DTT on the stability of EC1 (Figure 2.2a). 
 At pH 7.0, the amount of EC1 decreased to about 76 % after 4 h in the absence of 
DTT (Figure 2.2b). No new peak was observed, suggesting that the loss of EC1 was 
presumably due to precipitation. In contrast, the loss of EC1 to precipitation after 4 h 
in the presence of DTT at pH 7.0 was only 6% (Figure 2.2b).  
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Figure 2.2a: The stability profile of EC1 incubated at 37 °C for 4 h in the absence and 
presence of 0.1 M DTT in buffer solutions at pH 3.0. In the absence of DTT, there is 
some loss in the amount of EC1, presumably due to precipitation, since no new peaks 
were observed on the HPLC under these conditions. 
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Figure 2.2b: The stability profile of the EC1 domain incubated at 37 °C for 4 h in the 
absence and presence of 0.1 M DTT in buffer solutions at pH 7.0. 25% EC1 was lost 
after 4h due to precipitation, in the absence of DTT. In the presence of 0.1 M DTT, 
however, only 6% of EC1 precipitated after 4 hours. 
 
 
 
 
 
 
 59
0
10
20
30
40
50
60
70
80
90
100
110
0 1 2 3 4
Incubation Time (h)
%
 P
ro
te
in
 R
em
ai
ni
ng
No DTT
Prod. 1 w/o DTT
DTT
Prod. 1 w DTT
 
Figure 2.2c: The stability profile of the EC1 domain incubated at 37 °C for 4 h in the 
absence and presence of 0.1 M DTT in buffer solutions at pH 9.0 studied by 
monitoring the loss in area under the peak of EC1 and appearance and increase in the 
area under a new peak on HPLC. In the absence of DTT, about 27% of EC1 degraded 
to form a new product. In the presence of 0.1 M DTT, however, only 13% of EC1 
degraded to form the new product. 
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Figure 2.2d: ESI (+ve)- TOF MS of the degradation product of EC1 
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At pH 9.0, however, a chemical degradation product appeared over time (Figure 
2.2c) with a molecular weight of 10,386 Da as determined by ESI positive TOF-MS  
 (Figure 2.2d). In the absence of DTT, the amount of the degradation product was 
almost 27% and the amount of EC1 decreased to 73% (Figure 2.2c). In the presence 
of DTT, however, the amount of the degradation product was only about 12%, and 
the amount of DTT decreased to 87% (Figure 2.2c). Thus, no precipitation is 
observed at pH 9.0. The degradation product corresponds to a protein fragment 
resulting from the cleavage of the peptide bond between the Asp93 and Pro94 
residues (Figure 2.1a).  
Thus, DTT supresses the precipitation as well as the peptide bond hydrolysis 
degradation of EC1. 
Stability at 70 °C: The degradation of EC1 at pH 3.0 and 70 °C was rapid 
compared to that at 4 °C and 37 °C with about 25% and 5% of EC1 remaining in 
solution after 2 h and 4 h incubation, respectively (Figure 2.3a). After 30 min, the 
degradation product with a molecular weight of 10,386 Da was observed as 
previously found at pH 9.0 and 37 °C. This product was identified previously as the 
product of hydrolysis of the Asp94-Pro94 peptide bond. An increase in the 
degradation product, from 20% to 40%, was seen during 0.5 to 2.0 h incubation 
followed by a drop in product amount to 12% at the 4 h incubation time. The decrease 
in the degradation product in solution and the lack of mass balance suggest that 
besides peptide bond hydrolysis, the degradation of EC1 also involves a precipitation  
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Figure 2.3a: The stability profiles of the EC1 domain incubated at 70 °C for 4 h in the 
absence and presence of 0.1 M DTT in buffer solutions at pH 3.0 as determined by 
HPLC analysis. In the absence of DTT, EC1 undergoes some peptide bond 
hydrolysis, but mostly precipitation. In the presence of 0.1 M DTT, however, the 
extent of precipitation of EC1 after 4 h is decreased and no hydrolysis product is seen. 
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Figure 2.3b: The stability profiles of the EC1 domain incubated at 70 °C for 4 hin the 
absence and presence of 0.1 M DTT in buffer solutions at pH 7.0 as determined by 
HPLC analysis. EC1 undergoes hydrolysis of the peptide bond (12% after 4 h) and 
precipitation (70% after 4 h). In the presence of DTT, however, the extent of peptide 
bond hydrolysis is decreased (6% after 4 h) and so is the precipitation of EC1 (40% 
after 4 h). 
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Figure 2.3c: The stability profiles of the EC1 domain incubated at 70 °C for 4 h in the 
absence and presence of 0.1 M DTT in buffer solutions at pH 9.0 as determined by 
HPLC analysis. In the absence of DTT, 53% EC1 undergoes peptide bond hydrolysis 
after 4 h. In the presence of 0.1 M DTT, however, the peptide bond hydrolysis is 
decreased to 27% after 4 h. 
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reaction. Again, it is found that DTT decreases the precipitation and completely 
suppress the peptide bond hydrolysis degradation. The degradation of EC1 at pH 7.0 
(Figure 2.3b) also showed a two-stage profile of loss of EC1 in which an initial stage 
is seen from 100% to 67% between 0 and 2 h and a second from 67% to 15% between 
2 and 4 h. A peptide bond hydrolysis product, similar to that seen at pH 3.0 but in a 
lower amount (20% after 2 hours), was found at pH 7.0, which implies that the 
degradation rate was slower at pH 7.0 than pH 3.0. Also, under these conditions, 70% 
of EC1 was presumably lost to precipitation, due to the lack of mass balance. The 
addition of DTT inhibited the rate of peptide bond hydrolysis as well as precipitation 
of EC1.  
EC1 had the greatest amount of chemical degradation product at pH 9.0 (Figure 
2.3c) compared to that at pH 3.0 and 7.0. Again, the production of the peptide bond 
hydrolysis product was suppressed by the presence of DTT. In addition, the amount 
of starting material remaining in solution is higher at pH 9.0 than at pH 3.0 or 7.0 at 
the 4 h time point, which suggests less precipitation of EC1 at pH 9.0 than at pH 3.0 
and pH 7.0. 
 
2.3.2. Physical Stability of EC1: 
2.3.2.1. Secondary structure evaluation using CD: At pH 3.0, the CD spectrum of 
EC1 has a negative peak around 216 nm before incubation (Figure 2.4a, day 0), 
suggesting that it has a predominantly β-sheet structure. This is consistent with the 
known structures of EC domains. Addition of DTT caused some change in the  
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Figure 2.4a: CD spectra of EC1 in the absence and presence of DTT after incubation 
at 4 °C for 0, 14, or 28 days at pH 3.0. In the absence of DTT, EC1 undergoes 
secondary structural change presumably due to dimerization and oligomerization. In 
the presence of 2 mM DTT, there is no secondary structural change in EC1. 
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Figure 2.4b: CD spectra of EC1 in the absence and presence of DTT after incubation 
at 4 °C for 0, 14, or 28 days at pH 7.0. After 28 days, there is some loss of the β-sheet 
structure of EC1 in the absence of DTT as seen from the decrease in the minimum at 
216 nm; addition of 2 mM DTT suppresses the secondary structural change of EC1. 
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Figure 2.4c: CD spectra of EC1 in the absence and presence of DTT after incubation 
at 4 °C for 0, 14, or 28 days at pH 9.0. After 28 days, the CD spectra remain 
unchanged in the presence and absence of DTT. 
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secondary structure of EC1. Upon storage of EC1 for 14 days at 4 °C without DTT, 
its CD spectrum was dramatically changed compared to the original spectrum and 
showed increasing β-sheet character. This could be due to oligomerization via β-sheet 
intermolecular interactions. Addition of DTT suppressed the change in the CD spectra 
of EC1 between day 0 and day 14 (Figure 2.4a), suggesting that DTT inhibits the 
aggregation of the EC1 protein. At pH 7.0 (Figure 2.4b), the CD spectral changes 
were less dramatic compared to that at pH 3.0 (Figure 2.4a). The major changes in the 
CD spectra of EC1 at pH 7.0 after incubation for 14 and 28 days without DTT were in 
the minimum at 216 and the maxima at 205nm (Figure 2.4b). Addition of 2.0 mM 
DTT into the buffer suppressed the spectral change upon incubation for 28 days. 
There were no observable changes in the CD spectra of EC1 at pH 9.0 after 28 days 
in the presence and absence of DTT (Figure 2.4c). 
The melting curves of EC1 were monitored at 218 nm and compared in the absence 
and presence of DTT (Figure 2.5a). At pH 3.0 without DTT, the melting curves of 
EC1 were dramatically different between day 0 and day 14, with a more negative 
ellipticity minimum observed at day 14 than that at day 0 (Figure 2.5a). The melting 
temperatures (Tm) were 28.8 °C on day 0 and 33.1 °C on day 14, indicating that the 
protein could form oligomers with a higher Tm. In contrast, the thermal unfolding 
curves of EC1 on days 0 and 14 were very similar in the presence DTT (Figure 2.5a). 
At the final melting temperature, the protein solution containing DTT has a lower 
minimum than that of protein without DTT, indicating that the β structure  
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Figure 2.5a: Thermal unfolding profiles of EC1 in the absence and presence of DTT 
measured by CD at 218 nm after incubation for 14 to 28 days at 4 °C at pH 3.0. The 
thermal unfolding profiles in the absence of DTT are different on day 14 compared to 
that on day 0; in the presence of DTT, the profiles look the same on days 0 and 14. 
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Figure 2.5b: Thermal unfolding profiles of EC1 in the absence and presence of 
DTT measured by CD at 218 nm after incubation for 14 to 28 days at 4 °C at pH 7.0. 
The thermal denaturation profiles in the absence of DTT are different at different time 
points; however, the profiles are relatively the same in the presence of DTT. 
 
 
 
 
 
 
 72
10 20 30 40 50 60 70
-600000
-550000
-500000
-450000
-400000
-350000
-300000
-250000
-200000
-150000
-100000
M
ol
ar
 e
lli
pt
ic
ity
 (d
eg
.c
m
2 /d
m
ol
)
Temperature (°C)
No DTT, Day 0
No DTT, Day 14
No DTT, Day 28
DTT, Day  0
DTT, Day  14
DTT, Day  28
 
Figure 2.5c: Thermal unfolding profiles of EC1 in the absence and presence of DTT 
measured by CD at 218 nm after incubation for 14 to 28 days at 4 °C at pH 9.0. The 
thermal denaturation profiles are comparable after incubation for 14 and 28 days in 
the presence or absence of DTT. 
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of the protein at high temperature in the absence of DTT was increased compared to 
that in the presence of DTT. 
At pH 7.0, thermal unfolding of EC1 at days 0, 14, and 28 in the presence of DTT 
did not show a difference in melting temperature (Tm = 44.6 °C, Figure 2.5b). 
Without DTT, thermal denaturation curves at pH 7.0 gradually shifted from day 0 to 
day 28 to the increased initial and final ellipticities; this result is different than the one 
observed at pH 3.0, suggesting that the structure of the intermediates at pH 7.0 is 
different than those at pH 3.0. The presence of DTT prevented the change in thermal 
unfolding curves over time, again suggesting that DTT prevented the physical 
degradation of EC1. Thermal denaturation of EC1 at pH 9.0 showed a Tm at 37.8 °C 
(Figure 2.5c) with a slightly higher Tm when incubated up to day 28. At pH 9.0, DTT 
did not have a dramatic effect on the melting curve profiles of the EC1 domain at the 
different time points, which remained around 38 °C.  
2.3.2.2. Evaluation of tertiary structural changes by fluorescence spectroscopy: The 
intrinsic fluorescence emission spectrum of EC1 at pH 3.0 on day 0 without DTT 
showed a maximum emission at 339.93 ± 0.04 nm. There was no observable change 
upon incubation for 14 days (data not shown). After 28 days, a slight blue shift of 3.0 
nm (337.09 ± 0.04 nm) in the maximum emission was observed, implying that the 
Trp residue environment became more apolar. In the presence of DTT on day 0, EC1 
showed an emission profile (339.85 ± 0.04 nm) similar to that in the absence of DTT. 
A blue shift to 337.35 ± 0.04 nm was also observed after incubation for 28 days. At 
pH 7.0 without DTT, the emission maximum was 339.27 ± 0.03 nm; after incubation  
 74
0
100000
200000
300000
400000
500000
600000
305 315 325 335 345 355 365 375 385 395 405
Wavelength (nm)
E
m
iss
io
n 
(c
ou
nt
s/
se
c)
No DTT, Day 0
No DTT, Day 28
DTT, Day 0
DTT, Day 28
 
Figure 2.6a: Intrinsic fluorescence emission spectra of EC1 (after excitation at 295 
nm) in the absence and presence of DTT after incubation at 4 °C for 0 or 28 days at 
pH 7.0. A shift in the emission maximum to a higher wavelength is observed in the 
absence of DTT; however, this shift is inhibited by addition of DTT. 
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Figure 2.6b: Thermal unfolding of EC1 in the absence and presence of DTT evaluated 
by change in the wavelength of maximum intrinsic fluorescence emission (after 
excitation at 295 nm) from 0 °C to 87.5 °C after incubation for 0, 14, or 28 days at 
4 °C and pH  7.0. 
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for 28 days, there was a considerable red shift in the emission maximum to 345.81 ± 
0.13 nm, presumably due to increased solvent exposure of the Trp residues (Figure 
2.6a). The presence of DTT prevented the red shift in the emission maximum from 
339.26 ± 0.03 nm on day 0 to 340.66 ± 0.04 nm on day 28. Without DDT at pH 9.0, 
the intrinsic fluorescence spectra showed a slight blue shift from 341.32 ± 0.03 nm on 
day 0 to 340.32 ± 0.03 nm and 340.08 ± 0.03 nm on days 14 and 28, respectively 
(data not shown). DTT also did not prevent the shift in maximum emission from 
341.06 ± 0.03 nm on day 0 to 341.19 ± 0.02 nm and 341.42 ± 0.03 nm on days 14 and 
28, respectively. Thus, DTT could not prevent the change in EC1 tertiary structure 
upon incubation for 28 days at different pH values. 
The thermal transitions of EC1 at pH 3.0, 7.0, and 9.0 were also monitored by 
fluorescence spectroscopy at the emission wavelength of 340 nm upon heating from 
10 °C to 87.5 °C. At pH 3.0, there was no clear and observable transition seen in the 
absence or presence of DTT at all time points (data not shown). Distinct thermal 
transitions, however, were observed at pH 7.0 in both the absence and presence of 
DTT (Figure 2.6b). In the absence of DTT, the transition temperature decreased from 
42.63 ± 0.56 °C at day 0 to 39.10 ± 2.31 °C at day 28. On the other hand, relatively 
constant transition temperatures were observed in the presence of DTT between day 0 
(45.36 ± 0.79 °C) and day 28 (45.14 ± 0.65 °C). At pH 9.0, transitions were observed 
on day 0 in the absence and presence of DTT; these transitions did not change 
significantly after incubation for 28 days with and without DTT (data not shown). 
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2.3.3. Molecular Dynamics Simulations of EC1 Monomer and Dimer:  
To explain the difference between the stability of EC1 monomer and dimer, 10 ns 
equilibrium simulations were conducted on both in solution. EC1 from the structure 
PDB code: 1EDH was used as the starting point. To explore their dynamic stability, 
root-mean-square displacement (RMSD) values for the protein Cα atoms were 
calculated and plotted during the production phase relative to the starting structures 
for the EC1 monomer (Figure 2.7, panel A) and dimer (Figure 2.7, panel B). The 
RMSD plots indicate that the structures of the EC1 monomer (Figure 2.7, panel A) 
achieve equilibrium much faster than those of the dimer (Figure 2.7, panel B); the 
dimer achieves equilibrium after approximately 3 ns of simulations. The RMSD 
fluctuations of the monomer are within 1.5 Å of the initial structure while the RMSD 
deviations of the dimer are in the range of 3.5–4.0 Å. Root-mean-square fluctuations 
(RMSF) were also plotted against the residue number for the monomer (Figure 2.8, 
panel A) and both chains of the dimer (Figure 2.8, panel B). The average RMSF value 
per residue of the dimer is larger than that of the monomer, demonstrating that the 
dimer has larger overall flexibility than the EC1 monomer. Structural snapshots of the 
monomer and dimer after 2, 5, 7, and 10 ns simulations are shown in Figures 2.9a and 
2.9b, respectively. All four structures are very stable without noticeable differences. 
In contrast, there are significant differences among the snapshot structures of the 
dimer, with some of the regions showing increased dynamic properties. The increased 
dynamic properties of the disulfide-mediated EC1 dimer may explain the decreased 
chemical and physical stability of the dimer. 
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Figure 2.7: RMSD values for 10 ns simulation of EC1 monomer (panel A) and EC1 
dimer (panel B). 
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Figure 2.8: RMSF values for each residue in EC1 monomer (panel A) and in both A 
and B chains of EC1 dimer (panel B) at the end of 10 ns equilibrium simulations. 
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Figure 2.9a: Snapshots of EC1 monomer after 2, 5, 7 and 10 ns of molecular 
dynamics simulation. 
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Figure 2.9b: Snapshots of EC1 dimer after 2, 5, 7 and 10 ns of molecular dynamics 
simulation. 
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2.4. Discussion 
During the expression of the EC1 domain, the protein is found as a mixture of 
monomers, dimers, and oligomers, which can be separated by size exclusion 
chromatography (SEC).13 The dimer is formed by an intermolecular disulfide bond 
between two Cys13 residues from each monomeric unit. It is proposed that the 
oligomers are formed by physical interaction of the dimer molecules. Under reducing 
conditions, the EC1 domain shows only one monomeric band upon SDS-PAGE, 
confirming that the dimer is the result of intermolecular disulfide formation at Cys13. 
Previously, we have also shown that an Ala mutation of the Cys residue prevents the 
formation of both dimers and oligomers.13 The fact that EC1 monomers do not 
oligomerize before forming covalent dimers leads us to hypothesize that the 
structures of EC1 monomer and covalent dimer are different. In this work, we 
evaluated the chemical stability of EC1 and the changes in its structure in the absence 
and presence of the reducing agent, DTT.  
In general, the accelerated thermal degradation mechanism of EC1 in solution 
involves chemical degradation and aggregation that leads to protein precipitation. The 
mass balance between the degradation products and the remaining starting material in 
solution did not add up to 100%; this difference in mass balance is presumably due to 
protein precipitation. The EC1 domain also showed hydrolysis products at all pH 
values at 70 °C while at 37 °C, this hydrolysis was only observed at pH 9.0. The 
 83
degradation products were the result of a peptide bond hydrolysis between Asp93 and 
Pro94 residues as identified by ESI MS. Base-catalyzed hydrolysis of the Asp-Pro 
peptide bond has been reported previously in peptides and proteins, including peptide 
bond cleavage of Asp133–Pro134 in recombinant human interleukin 1119 and 
Asp169-Pro170 in recombinant human macrophage colony stimulating factor.20 It has 
been previously reported that the peptide and protein degradation mechanisms at Asp 
residues were different at different pH values (acidic, neutral, and basic).21,22 At pH < 
5.0, the major degradation products are derived from peptide bond hydrolysis at the 
N- and C-termini of target Asp residue via the anchimeric assistance of the carboxylic 
acid side chain of the Asp residue. At neutral and basic conditions (pH > 6.0), the 
degradation mechanism is through a cyclic-imide intermediate formation that can 
produce iso-Asp as well as the related hydrolysis products.21,22 Due to the absence of 
the amide hydrogen in the Asp-Pro peptide bond of EC1, the degradation of EC1 in 
neutral and basic conditions can not proceed through the cyclic-imide intermediate; 
thus, it was expected that Iso-Asp product would not be observed as a degradation 
product of EC1. An important finding here is that addition of DTT suppresses or 
completely eliminates the Asp93-Pro94 peptide bond hydrolysis. Because in the 
presence of DTT only the monomeric form exists in solution, the results suggest that 
the hydrolysis of the EC1 monomer may be catalyzed by dimeric and/or oligomeric 
forms of EC1. In other words, the monomeric form is chemically more stable than the 
dimer and oligomer forms; thus, the EC1 domain can be stabilized against peptide 
bond hydrolysis by trapping it in its monomeric form.  
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The effect of 4 °C storage on the secondary structure and physical stability of 
EC1 in the absence and presence of DTT was evaluated by far UV CD.  EC1 shows a 
negative CD peak at 216 nm at all pH values, which is characteristic for β-sheet 
proteins; the X-ray1 and NMR4 structures of EC1 show that it has 7 β-strands and two 
small α-helices. After storage at 4 °C for 14 days at pH 3.0 in the absence of DTT, the 
CD spectrum changed dramatically with the peak at 216 nm becoming more negative. 
This could imply the formation of aggregates via the formation of intermolecular β-
sheet interactions. In contrast, there was no change in the CD spectrum after 14 days 
incubation in the presence of DTT, indicating that there was no secondary structural 
change. It should be noted that addition of DTT at pH 3.0 changes the spectrum of 
EC1 on day 0, suggesting that DTT induces a secondary structural change in EC1 that 
prevents the physical degradation of EC1 at pH 3.0 upon 4 °C storage (Figure 2.5a). 
At pH 7.0 and 9.0, there were no observable changes in the CD spectra of EC1 with 
DTT on day 0 and day 28. Upon incubation of EC1 in the absence of DTT, there were 
observable changes in the CD spectrum on day 28 compared to that on day 0.  
To further differentiate the effect of DTT on the thermal stability and possible 
oligomerization of EC1, thermal unfolding profiles of EC1 after incubation at 4 °C at 
0, 14, and 28 days were determined by monitoring the CD spectra at 218 nm. At pH 
3.0, thermal denaturation profiles at days 0 and 14 were very similar in the presence 
of DTT but were very different in its absence. This suggests that there are protein 
structural changes (i.e., oligomerization) upon incubation in the absence of DTT. In 
the absence of DTT at pH 7.0, CD spectra of EC1 changed after storage for 14 and 28 
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days; in contrast, there was no observable change in the presence of DTT. At pH 9.0, 
thermal unfolding properties of EC1 did not change significantly upon storage at 4 °C 
in the absence and presence of DTT. These results suggest that the secondary 
structures of monomer and covalent dimer are very similar at pH 9.0; however, they 
are different at lower pH. 
Changes in the tertiary structure of EC1 upon incubation under different 
conditions were also monitored by observing the emission spectra of Trp6 and Trp63 
in EC1 using fluorescence spectroscopy. The Trp6 residue is located close to Cys13.  
We hypothesize that the formation of intermolecular disulfide between two Cys13 
residues can cause a change in the conformation of EC1 that alters the environment of 
one or both Trp residues. There was considerable change in the environment of at 
least one of the Trp residues over a period of 28 days incubation at 4 °C at pH 3.0 and 
7.0. In the case of pH 7.0, there was a red shift indicating a more apolar environment 
for one or both Trp residue; in contrast, a blue shift was observed at pH 3.0, 
indicating a more apolar environment of the Trp residue. Thus, the resulting tertiary 
structures or association states of EC1 were different at these two pH values (i.e., 3.0 
and 9.0). The addition of DTT prevented the fluorescence change at pH 7.0 but not at 
pH 3.0. This is in contrast to the CD data in which addition of DTT prevented a 
change in the secondary structure of EC1 at both pH 3.0 and 7.0. The Trp6 residue 
has been shown previously to be involved in domain swapping to form EC1 physical 
dimers, suggesting that the fluorescence changes seen could be due to the 
contribution of Trp6 domain swapping upon covalent dimer formation. At pH 3.0, the 
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formation of the intermolecular disulfide may be slowed, resulting in a predominance 
of domain swapped physical dimers, which subsequently oligomerize. In such 
structures, the Trp6 would be expected to be buried, and hence the blue shift at pH 
3.0 
Our findings show that the formation of a covalent dimer induces chemical and 
physical instability; in an attempt to explain this observation, the dynamic properties 
of the EC1 monomer and dimer were examined using computer simulations. 
Previously, molecular dynamics simulations were done to determine the dynamic 
properties of the EC1–2 portion of E-cadherin in the presence and absence of Ca2+ 
ions. These simulations confirmed that apo-cadherin shows much higher 
conformational flexibility on a nanosecond timescale than does the calcium-bound 
form.23 The results from the current molecular dynamics simulations showed that the 
EC1 dimer had a greater mobility than did the EC1 monomer. In the EC1 dimer, 
some hydrophobic residues that would be expected to be folded into the core of the 
protein were found to be solvent-exposed at the end of the molecular simulations. 
Intermolecular interactions of these exposed hydrophobic residues on several EC1 
dimers could be the driving force for the formation of oligomers in solution. These 
dramatic conformational changes were not observed in the simulation of the EC1 
monomer; thus, keeping the EC1 domain in the monomeric form with DTT prevents 
its oligomerization. The formation of a covalent dimer could make the Asp93 and 
Pro94 residues more exposed to the solvent, leaving the Asp93–Pro94 peptide bond 
susceptible to hydrolysis. This supports our experimental observation that an increase 
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in dimeric forms enhances peptide bond hydrolysis products between Asp93 and 
Pro94. These molecular simulations data support the hypothesis that the formation of 
oligomers may be via the covalent EC1 dimer.  The formation of a covalent dimer of 
EC1 induces a change in conformation that results in the Asp-Pro peptide bond 
becoming more solvent-exposed and thus susceptible to hydrolysis. 
In conclusion, this study shows that EC1 degradation is mediated by the 
formation of an EC1 covalent dimer via its Cys13 residue. This covalent dimer 
induces a conformational change in EC1 that is prone to produce oligomers, which in 
turn lead to precipitation, and to facilitate chemical hydrolysis. The results of the 
molecular dynamics simulations support the experimental findings that the 
monomeric form is chemically more stable than the dimeric and oligomeric forms. 
Thus, prevention of covalent dimer formation by alkylating the thiol group could be 
an alternative method to stabilize the EC1 domain in solution without addition of a 
reducing agent. The alkylation of the thiol group of Cys13 will provide EC1 
monomer that can potetntially be used to block E-cadherin-mediated homotypic and 
heterotypic cell-cell adhesion for pharmaceutical applications. 
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Chapter 3 
Improving the stability of EC1 by modification of its  
Cys13 thiol group by alkylation 
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3.1. Introduction 
E-cadherins are intercellular proteins found in the adherens junctions of the 
intestinal mucosa and the blood-brain barrier. They create cell-cell adhesion by cis- 
and trans-homophilic interactions. The cis-interactions are generated between E-
cadherins on the same cell and the trans-interactions are produced by E-cadherins 
from opposing cells. It has been proposed that the cis-interactions are necessary for 
the formation of the trans-interactions that generate intercellular adhesion.1,2 The 
extracellular portion of E-cadherin involved in the cis- and trans- interactions is 
composed of five domains, numbered EC1-EC5. EC1 is the N-terminal domain of E-
cadherin and is located farthest from the cell surface. The EC1 domain has been 
shown to have an important role in the formation of cis- and trans-interactions. EC1 
has also been shown to be important for the selectivity of E-cadherin in creating the 
homophilic interactions.1-7 There are several proposed mechanisms of E-cadherin 
interactions that mediate cell-cell adhesion, and some of these mechanisms involve 
domain swapping between the Trp2 residue of EC1 from one E-cadherin molecule 
and a hydrophobic pocket of EC1 from another E-cadherin molecule. Due to the 
important role of the EC1 domain, we expressed and evaluated the recombinant 
human EC1 protein for its use as an inhibitor of E-cadherin-mediated cell-cell 
adhesion. 
EC1 and peptides derived from EC1 have been shown to inhibit cell-cell adhesion 
mediated by homophilic interactions of E-cadherins.8-11 Unfortunately, the EC1 
protein is unstable during storage (i.e., 4 weeks at 4 °C) after its purification. It 
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produces a covalent dimer via an intermolecular disulfide bond between the Cys13 
residues of two monomers, followed by the generation of oligomers and precipitation. 
The presence of oligomers and precipitates may interfere with studies designed for 
the evaluation of the biological activity of EC1. The covalent dimerization and 
physical oligomerization of EC1 have been determined by SDS-PAGE and size 
exclusion chromatography (SEC),12,13 as well as by monitoring changes in its far UV 
circular dichroism (CD) spectra and intrinsic fluorescence emission spectra after 
storage at 4 °C. Accelerated stability studies at different pH values (3.0, 7.0, and 9.0) 
and temperatures (37 °C and 70 °C) have shown that the EC1 protein undergoes 
hydrolysis at the D93–P94 peptide bond. Molecular dynamics simulation studies have 
indicated that the formation of the intermolecular disulfide at Cys13 of EC1 is a 
highly feasible reaction and that the covalent dimer has an altered structure, which is 
more dynamic than the structure of monomeric EC1. The increased flexibility of the 
EC1 dimer could explain the susceptibility of the D93–P94 peptide bond to 
hydrolysis. The oligomerization, precipitation and hydrolysis of the D93–P94 peptide 
bond of EC1 have been shown to be significantly inhibited or completely eliminated 
by the addition of dithiothreitol (DTT), a thiol reducing agent. The presence of thiol 
reducing agents (i.e., DTT or glutathione) would be undesirable during biological 
activity studies (i.e., inhibition of cell-cell adhesion) of EC1 since they may affect the 
results of the cell adhesion assays.  Thus, an alternative method is needed to stabilize 
the monomeric form of the EC1 protein so it can be evaluated in biological assays 
and stored for a long period. 
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The formation of covalent dimers by Cys residues can be prevented by modifying 
the Cys thiol group irreversibly14 or by mutating the Cys residue with an Ala, Ser, or 
Thr residue. Previously, we have shown that mutation of the Cys residue to an Ala in 
EC1 prevents the formation of the EC1 oligomers.13 In this work, the thiol group of 
the Cys residue was modified to a thioether by reacting it with iodoacetic acid or 
iodoacetamide to produce the EC1-IA and EC1-IN derivatives, respectively. The 
reactions of Cys thiol with iodoacetic acid and iodoacetamide have been known for a 
long time15,16 and have been extensively applied to modify protein structure and 
stability.17-24 The iodoacetamide derivative of EC1 (EC1-IN) has the same total 
charge as the parent EC1 protein, but EC1-IA has an additional negative charge 
introduced in EC1. The secondary structure of EC1-IN was evaluated by far UV CD 
spectroscopy under different pH conditions. The chemical and physical stability of 
the EC1-IN derivative were compared to that of EC1. The EC1-IN derivative showed 
a better chemical and physical stability profile than did the parent EC1 only at pH 7.0.  
 
 
3.2. Materials and methods 
3.2.1. Production of Alkylated EC1: 
The EC1 protein (M.W. = 11,628 Da) was expressed in E. coli and purified in the 
presence of β-mercaptoethanol (BME) as previously described in Chapter 2. The EC1 
protein (0.2 mg/mL) was reacted in the dark with iodoacetamide (1.0 mM) for 4 h at 
pH 8.0 in a buffer containing 0.02 mM BME, 20 mM Tris and 4.0 M guanidine 
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hydrochloride (Gdn.HCl). The completion of the reaction was monitored and 
confirmed by matrix-assisted laser desorption/ionization (MALDI) mass spectrometry 
with time-of-flight (TOF) detection. The alkylated EC1 (EC1-IN) was refolded by 
employing a step-wise dilution method in which the concentration of Gdn.HCl was 
reduced from 4.0 M to 0.5 M with a 0.5 M decrease in each dilution step. The dilution 
step consists of the addition of an appropriate volume of a buffer containing 20 mM 
Tris at pH 8.0, followed by incubation at 4 °C for 8 hours. When the Gdn.HCl 
concentration reached 0.5 M, dialysis procedure was performed with an 8-kD 
membrane to remove the Gdn.HCl, BME, and the unreacted iodoacetamide. The 
entire procedure described above was repeated by replacing iodoacetamide with 
iodoacetic acid to produce the EC1-IA derivative. Far UV CD spectroscopy was used 
to determine the success of protein refolding. The CD spectra of EC1-IA and EC1-IN 
were compared with the CD spectrum of EC1. The EC1-IN protein has a spectrum 
identical to that of EC1 at pH 7.0. The EC1-IA protein, however, has a spectrum 
substantially different form that of the native EC1; thus, it was not investigated 
further in the stability studies. The EC1-IN protein was evaluated further for its 
stability. 
 
3.2.2. Chemical Stability Studies: 
The EC1-IN protein was dialyzed into pH 3.0, pH 7.0, and pH 9.0 buffers and 
incubated at a concentration of 86 μM in sealed vials at 4 °C, 37 °C, and 70 °C for 4 
hours in solutions buffered at pH 3.0, 7.0, and 9.0. The buffers used were 100 mM 
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phosphate for pH 3.0, 50 mM phosphate for pH 7.0, and 100 mM borate containing 
0.08 M NaCl for pH 9.0. Samples were drawn at 0, 0.5, 1.0, 2.0, and 4.0 h and 
immediately stored at –70 °C until subsequent High Performance Liquid 
Chromatography (HPLC) analysis was performed. The HPLC was equipped with a 
C18 column (Varian Microsorb; pore-size: 300 Å; dimensions 250 Χ 4.6 mm) for 
seaparation of the analytes. The protein solution (25 μL) was injected into the column 
and eluted at a rate of 1.0 mL/min. A gradient elution method incorporating  solvent 
A (94.9% double distilled water, 5% acetonitrile (ACN), and 0.1% TFA) and solvent 
B (100% ACN) was used. The gradient elution followed the sequence: 0% to 45% B 
from 0.0 to 2.0 min, 45% to 51% B from 2.0 to 12.0 min, at 51% B from 12.0 to 17.0 
min, 51% to 100% B from 17.0 to 19.0 min, at 100% B from 19.0 to 21.0 min, and 
100% B back down to 0% B from 21.0 to 22.0 min. A Varian Prostar UV detector at 
a wavelength of 220 nm was used to detect the proteins eluted from the column. 
MALDI-TOF MS analysis was used to determine the molecular weight of any new 
peaks observed on the HPLC chromatogram. 
 
 
3.2.3. Physical Stability Studies: 
Physical stability studies of EC1-IN were performed by monitoring the far UV 
CD spectra and the intrinsic fluorescence emission spectra on day 0 and after 14 and 
28 days after incubation at 4 °C at pH 3.0, 7.0 and 9.0. The buffering agents used 
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were the same as described in the chemical stability studies section. Concentration of 
EC1-IN used in these studies was 86 μM. 
 
3.2.3.1. Far UV CD studies: The secondary structural change of the EC1-IN 
protein was analyzed by far UV CD spectroscopy with a Jasco spectropolarimeter (J-
720) equipped with a Peltier temperature controller by loading 300 μL of EC1-IN into 
a sealed CD cuvette with 0.1 cm pathlength.25 The protein CD spectrum was 
measured at 10 °C between 200 and 250 nm. Triplicate spectra were obtained for 
EC1-IN, and the contribution of the buffer was eliminated by subtracting the the 
blank spectrum (containing the buffer alone) from the spectrum of protein in the same 
buffer. The same samples were also used for the thermal unfolding studies by 
recording their CD spectra at every 5 °C increase in temperature. The temperature of 
the cuvette holder was increased from 10 °C to 65 °C at a rate of 15 °C/h. The 
samples were equilibrated at the target temperature for 300 s before obtaining their 
spectra. The entire procedure was repeated after 14 and 28 days for EC1-IN samples 
stored at pH values of 3.0, 7.0, and 9.0 at 4 °C. The ellipticity at 218 nm (used to 
monitor changes in the β-sheet content) was plotted against the corresponding 
temperature and a sigmoidal function was used to fit the thermal unfolding curves 
using Origin 7.0 software. The midpoint of each transition in the sigmoidal fit was 
defined as the thermal unfolding temperature (Tm). 
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3.2.3.2. Intrinsic fluorescence emission studies: Changes in the tertiary structure 
of EC1-IN after 14 and 28 day incubation at 4 °C were monitored using fluorescence 
spectroscopy and compared to the emission profile on day 0.  For each experiment, 90 
μL of the EC1-IN protein (86 μM) was diluted to 0.9 mL with the appropriate buffer 
and transferred to a quartz fluorescence cuvette. The protein was excited at 295 nm 
(>95% Trp emission) and the fluorescence emission was observed between 305 and 
405 nm using a PTI QuantaMaster spectrofluorometer.26 Emission was set between 
500,000 and 1,000,000 counts/sec by adjusting the excitation and emission slits. The 
emission spectra were obtained in triplicate and the blank spectrum was subtracted 
from each of them. The thermal unfolding of the EC1-IN protein was followed by 
detecting the change in the wavelength of maximum emission for every 2.5 °C 
increase in temperature. The temperature was increased at a rate of 15 °C/h and the 
samples were equilibrated at each analysis temperature for 300 s before collecting 
their spectra. Again, three samples containing EC1-IN and one containing the buffer 
alone were used to perform each thermal unfolding experiment. Each fluorescence 
emission spectrum obtained was fitted to an extreme assymetric peak function using 
the non-linear curve-fitting wizard of Origin 7.0 software to obtain the wavelength of 
maximum emission. The entire procedure mentioned above was repeated once for 
each pH studied.  
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3.3. Results 
3.3.1. Alkylation of EC1: 
Alkylation of the Cys thiol group of EC1 with iodoacetamide or iodoacetic acid is 
represented in figure 3a. The alkylation produced  the desired product in a 
quantitative yield with one band in an SDS PAGE gel and a single peak on a 
reversed-phase HPLC C18 column. The products show the respective thioether of 
acetate (EC1-IA) and acetamide (EC1-IN) in the EC1 protein as determined by 
MALDI mass spectrometry (Figures 3.1b and 3.1c). The secondary structure of EC1-
IN has characteristics similar to those of the parent EC1 at pH 7.0, showing a 
minimum at 216 nm and maxima at 235 and 205 nm (Figure 3.1d). The secondary 
structure of EC1-IN is sensitive to pH changes; the CD spectra of EC1-IN at pH 3.0 
and 9.0 are different than its spectrum at pH 7.0 (Figure 3.1d). The minimum at 216 
nm at pH 7.0 shifted to 210 nm at pH 3.0 and 9.0, and this minimum is more 
pronounced at pH 3.0 than at pH 9.0. Furthermore, the spectra at pH 3.0 and 9.0 lack 
the maxima at 205 and 235 nm. Thus, these results suggest that EC1-IN has a 
secondary structure similar to that of the parent EC1 at pH 7.0, but at pH 3.0 and 9.0, 
it has a different secondary structure than does EC1. 
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SHEC1 + ICH2COO SEC1 CH2COO + HI
SHEC1 + ICH2CONH2 SEC1 CH2CONH2 + HI
Iodoacetate
Iodoacetamide
EC1
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EC1-IA
EC1-IN
 
Figure 3.1a: The alkylation reaction of the thiol group of the Cys13 residue of EC1 
with iodoacetate and iodoacetamide produces the EC1 derivatives EC1-IA and EC1-
IN, respectively. 
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Figure 3.1b: MALDI-TOF spectrum of EC1 alkylated with iodoacetic acid (EC1-IA) 
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Figure 3.1c: MALDI-TOF spectrum of EC1 alkylated with iodoacetamide (EC1-IN) 
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Figure 3.1d: The effect of pH on the secondary structure of EC1-IN as determined by 
CD spectroscopy. 
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3.3.2. Chemical stability of EC1-IN: 
The chemical stability of the EC1-IN protein was monitored by HPLC after 
incubation for 4 h at pH 3.0, 7.0, and 9.0 at 4 °C. Under these conditions, there was 
no observable decrease in the chromatographic peak of the EC1-IN protein. The area 
under the peak of EC1-IN did not show substantial changes. There was no appearance 
of a new peak for any degradation product over the 4 h incubation period (data not 
shown). These results indicate that the EC1-IN protein is stable upon incubation for 4 
h at 4 °C at all three pH values studied. 
The EC1-IN protein was also chemically stable at 37 °C at pH 3.0, 7.0, and 9.0 
(Figure 3.2a). Upon HPLC, there was no change in the area under the peak of EC1-IN 
and no new peaks representing degradation products were detected. In contrast, our 
previous studies showed that the parent EC1 was unstable when incubated for 4 h at 
pH 7.0 and 9.0 at 37 °C. Native EC1 degraded via hydrolysis of its D93-P94 peptide 
bond. These results imply that the EC1-IN protein is more stable to hydrolytic 
cleavage than the parent EC1 protein at 37 °C. 
The EC1-IN protein was also stable for 4 h at pH 7.0 and 9.0 at 70 °C (Figure 
3.2b), which is again in contrast to the results obtained for the stability study of the 
parent EC1 protein. Previously, the EC1 protein was shown to undergo hydrolysis of 
its D93-P94 peptide bond under similar conditions. At pH 3.0, however, a significant 
decrease of EC1-IN to 22% of the original amount was observed after 4 h incubation 
at 70 °C (Figure 3.2b). The disappearance of the HPLC peak of EC1-IN was 
accompanied by the appearance of a new peak with a molecular weight of 10,443.5  
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Figure 3.2a: The chemical stability profiles of EC1-IN after incubation for 4 h at pH 
3.0, 7.0, and 9.0 at 37°C. At 37 °C, EC1-IN does not undergo any chemical 
degradation or precipitation at pH 3.0, 7.0, and 9.0. 
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Figure 3.2b: The chemical stability profiles of EC1-IN after incubation for 4 h at pH 
3.0, 7.0 and 9.0 at 70 °C. EC1-IN shows no peptide bond hydrolysis or precipitation 
at pH 7.0 and 9.0. At pH 3.0, however, EC1-IN undergoes peptide bond hydrolysis as 
well as precipitation. The product of hydrolysis was identified as the N-terminal 
fragment G1-D93. 
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Da (the M.W. was determined using MALDI-TOF MS). This fragment is the product 
of hydrolysis of EC1-IN at its Asp93–Pro94 peptide bond. This degradation product 
is similar to the degradation product observed for the parent EC1 protein. Moreover, 
at pH 3.0, the increase in the peak area of the hydrolysis product did not correspond 
quantitatively to the decrease in the peak area of the EC1-IN protein. This suggests 
that at pH 3.0, the degradation of EC1-IN also involves aggregation that leads to 
precipitation. 
 
 
3.3.3. Physical stability of EC1-IN: 
3.3.3.1. Secondary structure studies using CD spectroscopy: The effect of 
incubating EC1-IN at pH 3.0, 7.0 and 9.0 at 4 °C for up to 28 days on its physical 
stability was studied by observing changes in its CD spectra and comparing the data 
to the CD spectra of the parent EC1 protein. At pH 3.0, the CD spectra of the EC1-IN 
protein did not change after incubation for 14 days. The CD spectrum of EC1, 
however, changed from day 0 to day 14 with a shift in the minimum at 216 nm and 
disappearance of the maxima at 235 and 205 nm (Figure 3.3a), suggesting an increase 
in β-sheet character that could be due to the formation of oligomer. The melting curve 
of EC1-IN was compared to that of EC1 by monitoring the change in the CD signal at 
218 nm (Figure 3.3b). At pH 3.0, there is no observable difference in the melting 
curve of EC1-IN after 14 day incubation, whereas a dramatic change is detected in  
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Figure 3.3a: Comparison of the CD spectra of EC1-IN and EC1 after their incubation 
at pH 3.0 for 14 days at 4 °C. The CD spectrum of EC1-IN does not change 
substantially after 14 days, whereas that of EC1 does. 
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Figure 3.3b: Comparison of the thermal unfolding curves of EC1-IN and EC1 
proteins after incubation for 14 days. There is no change in the thermal unfolding 
curves of EC1-IN whereas a clear change is seen in the thermal unfolding curve of 
EC1. The inset shows that the thermal unfolding curves of EC1-IN can be fitted to 
sigmoidal functions. 
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the melting curve of EC1 after 14 day incubation. These data imply that EC1-IN does 
not undergo changes, such as covalent dimerization or physical oligomerization when 
incubated at 4 °C for 14 days as does EC1. 
At pH 7.0, the CD spectra of EC1-IN protein did not change upon incubation at 0, 
14, and 28 days at 4 °C (Figure 3.4a). On the other hand, incubation of the EC1 
protein under the same conditions produced changes in the CD spectra after 28 days 
(Figure 3.4b). The melting curves of EC1-IN after incubation for 0, 14, and 28 days 
did not change, but the melting curves of the EC1 protein showed dramatic changes 
(Figure 3.4c), suggesting that EC1-IN did not undergo physical degradation upon 
incubation. 
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Figure 3.4a: The CD spectra of EC1-IN after its incubation at pH 7.0 for 14 and 28 
days at 4 °C. The CD spectrum of EC1-IN does not change substantially after 14 and 
28 days. 
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Figure 3.4b: The CD spectra of EC1 after its incubation at pH 7.0 for 14 and 28 days 
at 4 °C. The CD spectrum of EC1 changes substantially after 14 and 28 days, unlike 
that of EC1-IN shown in Figure 3.4a. 
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Figure 3.4c: Thermal unfolding profile of EC1 and EC1-IN measured by the CD 
signal at 218 nm after incubation for 0, 14 and 28 days at 4 °C at pH 7.0. There are 
limited differences in the thermal unfolding curves of EC1-IN, but dramatic 
differences are seen in the thermal unfolding curves of the EC1. EC1 has a higher 
transition temperature than EC1-IN, indicating that EC1-IN is less stable to thermal 
unfolding than EC1. 
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At pH 9.0, the CD spectra of the EC1-IN protein after 14 and 28 day incubation 
showed a dramatic shift of the minimum at 210 nm to 202 nm, indicating a change in 
the secondary structure upon incubation (Figure 3.5a). Conversely, the CD spectrum 
of EC1 did not change after incubation for 28 days (data not shown). The melting 
curves of both EC1-IN and EC1 did not show any dramatic change after different 
incubation periods. Overall, alkylation of the Cys13 residue of EC1 with 
iodoacetamide improves its physical stability at pH 3.0 and 7.0. This is probably due 
to the prevention of covalent dimer formation of EC1-IN. EC1-IN, however, is 
physically less stable than EC1 at pH 9.0. 
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Figure 3.5a: The CD spectra of EC1-IN after its incubation at pH 9.0 for 14 and 28 
days at 4 °C. The CD spectrum of EC1-IN after 14 and 28 days is substantially 
different from that on day 0. 
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Figure 3.5b: Thermal unfolding profile of EC1 and EC1-IN measured by the CD 
signal at 218 nm after incubation for 0, 14 and 28 days at 4 °C at pH 9.0. The thermal 
unfolding curves of EC1-IN are substantially different from those of EC1.The inset 
shows that the thermal unfolding of EC1-IN can be fit to sigmoidal functions. 
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3.3.3.2. Tertiary structure studies using fluorescence spectroscopy: Intrinsic 
fluorescence emission spectroscopy was employed to monitor changes in the 
microenvironment of the Trp residues in EC1-IN and EC1. The Trp emission profile 
indicates how buried or exposed the Trp residues of the protein are. This, in turn, can 
be an indicator of the state of the tertiary structure of the protein being studied. The 
primary structure of EC1 contains two Trp residues located at positions 6 and 66 from 
the N-terminus Trp6 and Trp 66. At pH 3.0, EC1-IN exhibited fluorescence emission 
spectra with maximum intensity at wavelengths 340.61 ± 0.08 nm on day 0 and 
338.91 ± 0.06 nm on day 28. This amounts to a blue shift of about 0.7 nm. The 
fluorescence emission spectra of EC1 showed a more pronounced blue shift of almost 
3 nm in the wavelength of maximum emission from 339.93 ± 0.04 nm to 337.09 ± 
0.04 nm after 28 day incubation at 4 °C. A blue shift indicates a possible burial of Trp 
residues, which could be a result of protein aggregation. Hence, our data suggest that 
at pH 3.0, EC1 undergoes more aggregation than EC1-IN. 
A similar comparison of the wavelength of maximum intensity between the 
fluorescence emission spectra of EC1-IN and EC1 at pH 7.0 showed a small blue 
shift of approximately 1 nm from 342.13 ± 0.05 nm on day 0 to 341.21 ± 0.05 nm on 
day 28 for EC1-IN, but a large red shift of more than 6 nm from 339.27 ± 0.03 nm to 
345.81 ± 0.13 nm for EC1 (Figure 3.6a). Thermal unfolding curves of EC1-IN and 
EC1 were obtained by plotting the wavelength of maximum intensity against 
temperature. The thermal unfolding profiles for EC1-IN at pH 7.0 on day 0 and day 
28 show one observable transition around 35 °C (Figure 3.6b). In contrast, EC1 has  
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Figure 3.6a: Comparison of the intrinsic fluorescence emission spectra of EC1 and 
EC1-IN (after excitation at 295 nm) after incubation at 4°C for 28 days at pH 7.0. A 
red shift of 4.33 nm in the wavelength of maximum emission is observed for EC1; 
however, such a shift is not observed for EC1-IN. 
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Figure 3.6b: Thermal unfolding of EC1 and EC1-IN evaluated by intrinsic 
fluorescence emission after incubation for 0 and 28 days at 4 °C and pH 7.0. EC1-IN 
has a lower transition temperature than EC1. After 28 days incubation at 4 °C, EC1 
shows a transition to wavelengths > 375 nm at higher temperatures, while EC1-IN 
does not show such a transition. The inset shows the same data, magnified by plotting 
a smaller wavelength range on the y-axis. 
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one transition around 35 °C on day 0, but displays two transitions after incubation for 
28 days at 4 °C with the second transition to very high wavelengths (>375 nm) above 
60 °C.  
At pH 9.0, the fluorescence emission spectra of EC1-IN and EC1 do not show 
significant differences. The wavelength of maximum EC1 emission shifts from 342.0 
± 0.0 nm on day 0 to 339.67 ± 1.15 nm on day 28. For EC1-IN emission spectra, the 
corresponding change is from 343.0 ± 1.0 nm on day 0 to 341.67 ± 0.58 nm. Overall, 
the fluorescence data obtained suggest that at pH 3.0, 7.0 and 9.0, the microclimate of 
the Trp residues in EC1-IN does not change significantly during an incubation period 
of 28 days at 4 °C. In contrast, emission spectra of EC1 at pH 3.0 and 7.0 and its 
thermal unfolding at pH 7.0 showed significant changes in the same incubation 
conditions. 
 
3.4. Discussion  
EC1 is a protein of interest because it has an important role in intercellular 
adhesion in epithelial and endothelial junctions. Improving the physicochemical 
stability of the EC1 protein is necessary for studying its binding properties to E-
cadherin peptides and other EC domains of E-cadherin. The EC1 domain of 
endothelial E-cadherin also has a role in the inflammatory process; it binds to αEβ7 
integrins on T-lymphocytes during their extravasation through the vascular 
endothelium.27 Thus, the EC1 protein has potential uses as a therapeutic agent to 
block T-cell-endothelium adhesion during inflammatory responses. It is, therefore, 
 122
necessary to stabilize the EC1 protein for its long-term use in in vitro and in vivo 
biological assays.  
The EC1 domain of E-cadherin has previously been shown to form covalent 
dimers in vitro through intermolecular disulfide bonds between the Cys13 residues of 
EC1 monomers.13 The covalent dimers subsequently oligomerize via physical 
interactions that lead to precipitation.13 It has also been shown conclusively that 
covalent dimer formation is necessary for the oligomerization process. Blocking the 
covalent dimerization with reducing agents (i.e., DTT) suppresses the oligomerization 
of EC1.13 Stabilization of EC1 with DTT, however, would not be a preferred strategy 
because it may interfere with the biological evaluation of EC1. To block 
intermolecular disulfide bond formation, we decided to modify the thiol group of the 
Cys13 residue with iodoacetate or iodoacetamide to form the alkylated products, 
EC1-IA and EC1-IN, respectively. Although the X-ray structure of EC1 shows that 
the Cys13 residue is exposed on the surface of EC1, the alkylation reaction of the 
thiol group of the folded form of EC1 was slow. The alkylation reaction was 
accelerated in the presence of 4 M Gdn.HCl. The subsequent slow removal of 
Gdn.HCl refolded the iodoacetamide derivative (EC1-IN) to a structure similar to the 
parent EC1 protein as determined by CD. Unfortunately, the iodoacetate derivative 
(EC1-IA) did not refold correctly since it failed to exhibit the expected β-sheet 
character similar to that of the parent protein (EC1). This may be due to the additional 
negative charge on EC1-IA, which could prevent its proper refolding by destabilizing 
a refolding intermediate through charge repulsion with other negatively charged 
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residues (such as Asp or Glu) or by stabilizing an undesirable intermediate through 
charge-charge attractive interactions (i.e. salt bridge). A survey of the literature shows 
that additional negative charges introduced by modification of proteins with 
iodoacetate can result in significant differences in protein structure and activity 
between the iodoacetate- and iodoacetamide- modified proteins. In a study on the 
S8C mutant of sorghum phosphoenolpyruvate carboxylase (PEPC), modification of 
the C8 residue with iodoacetate decreased the sensitivity of the mutant to L-malate by 
50%.22 This decrease in the activity of the mutant PEPC was attributed to the 
additional negative charge introduced by modification with iodoacetate.  In contrast, 
modification of the C8 residue with iodoacetamide, which did not introduce any 
additional charges in the protein, did not change the sensitivity of the mutant PEPC to 
L-malate. Due to the difficulty in folding EC1-IA, only the stability of EC1-IN was 
evaluated in this work. 
The secondary structure of EC1-IN was similar to EC1 at pH 7.0 as shown in the 
similarity of the CD spectra of both proteins. The estimated secondary structure 
content of EC1-IN was 47% β-sheet, 5% α-helix, and 48% random coil and that of 
EC1 was 51% β-sheet, 2% α-helix, and 47% random coil. These values are well 
within the experimental error of the estimation method.  The CD spectra of EC1-IN, 
were, however, dramatically different from those of the EC1 protein at pH 3.0 and 
9.0. Altered secondary structures of proteins due to carboxymethylation or 
carboxyamidomethylation have been previously reported. Alkylation of the thiol 
groups of ovalbumin with iodoacetate and iodoacetamide resulted in a structural 
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transition from α-helix to β-sheet.20 In another study, alkylation of completely 
reduced bovine serum albumin with iodoacetate and iodoacetamide led to a 
significant decrease in the α-helical content and a corresponding increase in β-sheet 
and random coil.21  The CD spectra of EC1-IN and EC1 imply that EC1-IN is more 
stable than EC1 after their incubation at pH 3.0 and 4 °C for 14 days (Figure 3.2a). 
This finding is corroborated by the changes in the fluorescence emission spectra of 
EC1-IN and EC1. There is no change in the emission spectra of EC1-IN, but there is a 
blue shift in the spectra of EC1 after incubation at 4 °C for 28 days. The melting 
temperature (Tm) of EC1-IN estimated from the change in its β-sheet character with 
increase in temperature is higher than the Tm of EC1 at both pH 3.0 and 9.0. At pH 
3.0, the Tm of EC1-IN is 39.9 ± 1.0 °C, whereas the Tm of EC1 is 28.853 ± 0.27 °C.  
At pH 7.0, however, the Tm of EC1-IN (33.9 ± 0.7 °C) is lower than the Tm of EC1 
(42.0 ± 0.6 °C). Decreased thermal stability of a protein due to its alkylation has been 
reported previously. For example, thermal unfolding curves for alpha alpha 
tropomyosin (AAT) obtained by monitoring the α-helical change in protein structure 
with increasing temperature revealed that AAT modified by iodoacetate and 
iodoacetamide showed decreased thermal stability compared to that of unmodified 
AAT.24 Although EC1-IN has a lower Tm at pH 7.0, there is no change in its CD 
spectra after incubation for 28 days. In contrast, these incubation conditions cause a 
change in the secondary structure of the parent EC1. The advantage of alkylating EC1 
is that the alkylation maintains the conformation of EC1 during long-term, low 
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temperature incubation, possibly by preventing formation of covalent dimers, which 
have an altered structure.  
The EC1-IN protein also has a higher chemical stability than that of native EC1 
with the peptide bond hydrolysis reaction only observed during incubation of the 
protein at pH 3.0 and 70 °C. In this case, the amount of EC1-IN was decreased to 
22% after 4 h incubation. Because the total amount of EC1-IN (22%) and the 
degradation product (10%) does not add up to 100%, the remaining 78% of EC1-IN 
could be in the form of insoluble material. Compared to EC1-IN, the EC1 is very 
unstable at 70 °C at all pH values studied. The precipitation of EC1 or EC1-IN may 
occur due to formation of an insoluble intermediate during their thermal unfolding 
process at 70 °C. At 37 °C, EC1-IN was stable to chemical degradation after 4 h at 
pH values of 3.0, 7.0 and 9.0. In contrast, EC1 is chemically stable only at pH 3.0 but 
not at pH 7.0 and 9.0, indicating that unmodified EC1 is more prone to form a 
covalent dimer at neutral and basic pH. Because alkylation of the thiol group 
enhanced the chemical and physical stability of EC1-IN compared to EC1 and 
addition of DTT to EC1 improved its stability, these results support the proposed 
hypothesis that the degradation of EC1 is mediated by dimer formation. Alkylating 
the thiol group thus eliminates the formation of the unstable covalent dimer. With the 
help of computational modeling, we have shown previously that the dimerization of 
EC1 is a facile reaction and it causes a different conformation of the two EC1 chains 
in the dimer compared to that of the monomeric form of EC1. The EC1 dimer is also 
more flexible than the monomer as shown by molecular dynamics simulations, thus 
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making the D93–P94 peptide bond susceptible to hydrolysis. Addition of DTT 
maintains EC1 in its monomeric form and decreases the hydrolysis of the D93–P94 
bond as well as maintains its structure during long-term (28 days) incubation at 4 °C. 
The intrinsic fluorescence emission spectra of EC1 at pH 7.0 previously had 
revealed a red shift of 4.33 nm from day 0 to day 28 in its wavelength of maximum 
emission (Figure 3.5a). The thermal unfolding of EC1 monitored by observing the 
change in wavelength of maximum emission with temperature also showed a 
significant difference between unfolding profiles on day 0 and day 28 (Figure 3.5b). 
This suggested a change in the microenvironment of at least one of the two Trp 
residues of EC1 and, therefore, a change in the tertiary structure of EC1. In contrast, 
the intrinsic fluorescence emission spectra of EC1-IN at pH 7.0 did not show a red 
shift from day 0 to day 28 (Figure 3.5a). The thermal unfolding profiles of EC1-IN at 
pH 7.0 on day 0 and day 28 were also very similar (Figure 3.5b), suggesting that there 
was no observable change in the tertiary structure of EC1. 
In conclusion, modification of EC1 by alkylating the thiol group improves the 
chemical stability of EC1-IN as well as its primary, secondary and tertiary structure 
during long-term storage at low temperatures at pH 7.0. At pH 3.0 and 9.0, however, 
the secondary structure of EC1-IN was significantly different than that of EC1. EC1-
IN also precipitated at pH 3.0 at high temperature. We hypothesize that modification 
of the Cys thiol of EC1 with a hydrophilic polymer such as PEG may decrease the 
precipitation of EC1 and EC1-IN observed at pH 3.0. It has been shown that 
PEGylation of a protein does not disrupt its structure, thereby maintaining its 
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activity.28,29 We therefore, performed site-specific PEGylation of the Cys13 thiol of 
EC1 and studied its stability profile. These results are described in Chapter 4. 
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Chapter 4 
PEGylation of the Cys13 thiol of EC1 improves its stability  
while retaining its structure 
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4.1. Introduction 
E-cadherins are cell adhesion glycoproteins located in the adherens region of 
intercellular junctions of the epithelial or endothelial tissues of biological barriers. 
The extracellular portion of E-cadherin consists of five extracellular (EC) domains 
(EC1-to-EC5) that are involved in mediating cell-cell adhesion by cis- and trans-
interactions. The cis-interactions (cis-dimers) are formed between two extracellular 
domains protruding from the same cell, and the trans-interactions are produced by 
protein-protein interactions from the opposing cells.1,2 The EC1 domain at the N-
terminal of E-cadherin has been shown to be important for the homophilic specificity 
of E-cadherin interactions in the adherens junctions.1-7 The EC1 protein and peptides 
derived from EC1 can inhibit E-cadherin-mediated cell-cell adhesion. The EC1 
protein, however, is very unstable upon long-term storage, contributing to difficulties 
in studying its in vitro and in vivo biological activities. 
The instability of the EC1 protein is due to covalent dimer formation followed by 
oligomerization and precipitation; thus, any method that prevents the dimerization of 
the EC1 protein might be beneficial for future studies of the EC1 domain. The 
covalent dimers of EC1 are produced by the formation of disulfide bonds between 
Cys13 residues of EC1 monomers; this is followed by oligomerization of the covalent 
dimers through non-covalent interactions. In addition, this protein also undergoes 
hydrolysis of its D93–P94 peptide bond. The presence of covalent dimers, physical 
oligomers, and hydrolysis products of EC1 in solution was characterized with the use 
of SDS-PAGE, size exclusion chromatography (SEC) and mass spectrometry.8,9 
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Molecular dynamics studies suggest that the formation of a covalent dimer makes the 
protein more dynamic, thereby contributing to the instability of the protein. The 
stability of the EC1 protein was shown to improve with the addition of dithiothreitol 
(DTT) to the protein solution as well as by modification of its Cys13 thiol group to 
thioacetamide (EC1-IN).  
In Chapter 3, we showed that the EC1-IN protein has the same conformation as 
the EC1 protein at pH 7.0. Its secondary structure, however, is sensitive to pH 
changes; at pH 3.0, and 9.0, its secondary structure is significantly different from that 
at pH 7.0. As an alternative approach to alkylation of the EC1 thiol, modification of 
the thiol group with polyethylene glycol (PEG) was attempted to improve the stability 
of EC1.10 PEGylation of therapeutic proteins has been shown to improve their 
physical and biological properties and lower their immunogenicity. PEGylation of a 
protein generally leads to an increase in its hydrodynamic radius, resulting in lower 
glomerular filtration and also increases its enzymatic stability. Thus, a higher 
systemic circulation of the parent protein is achieved, leading to a reduction in the 
dosing amount and dosing frequency. It has been proposed that protein PEGylation 
enhances the hydrophilic hydration shell around the protein thereby increasing the 
physicochemical stability of the protein. 
In this work, the EC1 protein was modified by alkylating the thiol group of Cys13 
with a PEG group activated with a maleimide functional group. Conjugation via the 
Cys residue is more selective than using the amino group of the Lys residue or the 
carboxylic acid groups of the Asp and Glu residues. Because EC1 has 7 Lys, 6 Asp, 
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and 9 Glu residues, the conjugation of a PEG group to these residues can produce a 
mixture of products with different numbers of attached PEG molecules. Due to the 
presence of only one Cys in the EC1 sequence, the PEGylation of EC1 produces a 
single product (PEGEC1), which has one molecule of PEG covalently linked to a 
molecule of EC1. PEGEC1 can no longer form disulfide-mediated covalent dimers. 
The structural characteristics of PEGEC1 were analyzed by circular dichroism (CD) 
and fluorescence spectroscopy, and the chemical stability of PEGEC1 was compared 
with that of the parent EC1 protein. The PEGEC1 shows a better physicochemical 
stability than the parent EC1.  
 
4.2. Methods 
4.2.1. Conjugation of EC1 with PEG:  
Maleimide-PEG (M.W. = 5,000 Da) was obtained from Sigma Chemicals Co. 250 
mg of maleimide-PEG was added to 50 mL of 20 mM Tris buffer at pH 8.0 
containing 0.2 mg/mL (0.17 mM) of recombinant human EC1 and 0.2 mM DTT. The 
reaction between the maleimide-PEG and EC1 was allowed to proceed by incubating 
this solution at 22 °C. After 2 hours, 50 μL of this solution was subjected to MALDI-
TOF MS analysis. The remaining solution was concentrated to 10 mL by passing it 
through a 10,000 Da cutoff membrane in an Amicon centrifuge tube and centrifuging 
at 4000 Χ g. The concentrated solution was stored at 4 °C until it was purified by 
(SEC). 
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4.2.2. Purification of the PEGEC1 conjugate:  
Three mL of the above concentrated solution was injected onto a Superdex 200 
size exclusion column. The mobile phase was 20 mM Tris buffered at pH 8.0. The 
column volume was 150 mL and the flow rate was 0.5 mL/min. The volume of the 
fractions collected was 3 mL. The separated PEG-EC1 conjugate (PEGEC1), EC1, 
and the maleimide-PEG were detected as separate peaks by their UV absorbance at 
280 nm. To estimate the yield of PEGylation, the unreacted EC1 was quantified by 
the area under its SEC peak and subtracted from the area under the peak of EC1 on 
the SEC before the reaction.  From these calculations, the yield of the PEGylated 
product was determined to be approximately 75%. The PEGEC1 fractions were 
pooled and concentrated to 7.5 mL. The concentration of PEGEC1 in this final 
solution was equal to 1 mg/mL of EC1 (86 μM). Fifty μL of this PEGEC1 solution 
was analyzed by MALDI-TOF analysis. The remaining PEGEC1 was used for 
chemical stability studies using high performance liquid chromatography (HPLC) 
analysis and structural studies using far UV CD spectroscopy and intrinsic 
fluorescence emission spectroscopy. 
 
4.2.3. Chemical stability studies of PEGEC1:  
Eighty six μM of PEGEC1 (equivalent to 1 mg/mL EC1) was dialyzed into 
solutions buffered at pH 3.0, 7.0 and 9.0 and incubated at 70 °C for 4 h. The 
composition of the buffers was 100 mM phosphate for pH 3.0, 50 mM phosphate for 
pH 7.0, and 100 mM borate containing 0.08 M NaCl for pH 9.0. After incubation at 
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70 °C for 4 h, the samples were transferred to a –70 °C freezer and stored until further 
analysis. HPLC was employed for the analysis of these samples. The HPLC system 
used was a Dynamax SD-200. The column used was a Varian Microsorb C18 (pore 
size 300Å, dimensions: 250 Χ 4.6 mm). Gradient elution at a rate of 1 mL/min was 
used for the separation. The two mobile phases used were A: 94.9% water, 5.0% 
acetonitrile, 0.1% TFA and B: 100% acetonitrile. A Varian Prostar UV detector was 
used to detect the eluted peaks at a wavelength of 220 nm. 
 
4.2.4. Structural studies of PEGEC1:  
Far UV CD spectroscopy and intrinsic fluorescence emission spectroscopy were 
used to characterize the secondary and tertiary structure, respectively, of PEGEC1. 
4.2.4.1. Far UV CD spectroscopy: A Jasco spetropolarimeter (J-720) equipped 
with a Peltier temperature controller was used to perform the CD spectroscopy 
studies. The CD spectra of PEGEC1 were obtained at 10 °C between 200 and 250 nm 
at pH 3.0, 7.0, and 9.0. For evaluation at each pH, 300 mL of 86 μM PEGEC1 was 
transferred to a CD cuvette of pathlength 0.1 cm. Three such cuvettes were used to 
obtain the CD spectra and the spectra were averaged after subtracting the blank signal 
from each spectrum. The blank signal was the CD spectrum obtained for a cuvette 
containing the corresponding buffer alone. Thermal unfolding studies were also 
performed for PEGEC1 at pH 3.0, 7.0, and 9.0.11 The temperature of the cuvette 
holder was increased from 10 °C to 65 °C at the rate of 15 °C/h, and the CD spectra 
of three cuvettes containing PEGEC1 in a buffer and one cuvette containing the 
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buffer alone were recorded. Thermal unfolding profiles were obtained for PEGEC1 at 
each pH studied by plotting the CD signal at 218 nm (to monitor changes in the β-
sheet content) against the corresponding temperature. The thermal unfolding plots 
were fitted to sigmoidal functions using Origin 7.0. The midpoint of each plot was 
used as the thermal unfolding temperature (Tm) of PEGEC1. 
 
4.2.4.2. Intrinsic fluorescence emission spectroscopy: A PTI Quantamaster 
spectrofluorometer was used to study the intrinsic fluorescence emission of PEGEC1. 
900 μL aliquots of 8.6 μM PEGEC1 at pH 3.0, 7.0, or 9.0 were transferred to a sealed 
quartz fluorescence cuvette. Three cuvettes containing protein and an additional 
cuvette containing the corresponding buffer were prepared and loaded into four 
position cuvette holder in the spectrofluorometer and equilibrated at 10 °C. These 
samples were then excited with UV light of wavelength 295 nm (>95% Trp 
emission), and their emission spectra were recorded between 305 and 405 nm.12 
Thermal unfolding of PEGEC1 also was studied at pH 3.0, 7.0, and 9.0 by increasing 
the temperature of the cuvette chamber from 10 °C to 87.5 °C at the rate of 15 °C/h, 
and the emission spectra were recorded at every 2.5 °C increase in temperature. After 
subtracting the blank emission signal from each PEGEC1 spectrum, the wavelength 
of maximum emission at each temperature point was plotted against the 
corresponding temperature. This plot, which provides the thermal unfolding profile of 
PEGEC1, was then fitted to a sigmoidal function using Origin 7.0 software. The 
wavelength of maximum emission for each fluorescence emission spectrum was 
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obtained by fitting the spectrum to an extreme asymmetric peak function using the 
non-linear curve-fitting wizard of Origin 7.0 software. Thermal unfolding profiles for 
PEGEC1 were plotted for each pH studied. 
 
4.3. Results 
The reaction between Cys thiol of EC1 and maleimide-activated PEG is shown in 
Figure 4.1a. The MALDI spectrum of the reaction mixture is shown in Figure 1b. The 
PEGEC1 was separated from EC1 and PEG by SEC, as mentioned previously (Figure 
4.1c). The HPLC peak of purified PEGEC1 (8.1 min) is shown in comparison to that 
of EC1 (8.4 min) and maleimide-activated PEG (7.9 min) (Figure 1d).  
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Figure 4.1a: Reaction of EC1 with maleimide-PEG. 
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Figure 4.1c: Separation of PEGylated EC1, unreacted EC1 and maleimide-PEG using 
size-exclusion chromatography. 
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Figure 4.1d: HPLC profiles of EC1 (panel A, retention time = 8.4 min), M-PEG 
(panel B, retention time = 7.4 min), and PEGEC1 (panel C, retention time = 8.1 min) 
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4.3.1. Chemical stability studies:  
The chemical stabilities of PEGEC1 at 70 °C incubation for 4 h at pH 3.0, 7.0, 
and 9.0 were analyzed by HPLC. At all three pH values studied, we found that the 
amount of PEGEC1, as given by the area under the HPLC peak, did not change 
substantially after incubation for 4 h at 70 °C (Figure 4.2). Moreover, no new peaks 
appeared in the chromatograms. This suggests that, at high-temperature, PEGEC1 is 
stable to precipitation and to chemical degradation reactions such as peptide bond 
hydrolysis. This result is in contrast to our previous studies that showed EC1 and its 
alkylated derivative (EC1-IN) underwent a peptide bond hydrolysis and/or precipitate 
formation under similar conditions. 
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Figure 4.2: Chemical stability studies of PEGEC1 at pH 3.0, 7.0, and 9.0 at 70 °C for 
4 h incubation. The results for the stability of PEGEC1 are compared with those for 
the stability of EC1 and EC1-IN obtained from Chapters 2 and 3. 
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4.3.2. Physical stability studies:  
4.3.2.1. Far UV CD results: Secondary structural changes in PEGEC1 were 
evaluated by far UV CD spectroscopy between 200 and 250 nm. Comparison 
between the CD spectra of PEGEC1 and EC1 at pH 3.0 showed minor differences 
between the two (Figure 4.3a). The PEGEC1 spectrum had more pronounced positive 
and negative peaks at 235 nm and 216 nm, respectively. At pH 7.0 and 9.0, however, 
there was no significant difference between the CD spectra of PEGEC1 and EC1 
(Figures 4.3b and 4.3c). 
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Figure 4.3a: Far UV CD spectrum of PEGEC1 compared to that of EC1 at pH 3.0. 
There are some differences between the two spectra. 
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 Figure 4.3b: Far UV CD spectrum of PEGEC1 compared to that of EC1 at pH 7.0. 
The two spectra are very similar. 
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Figure 4.3c: Comparison of the far UV CD spectra of PEGEC1 and EC1 at pH 9.0. 
shows that they are very similar. 
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Thermal unfolding of PEGEC1 also was studied from 10 °C to 65 °C at pH 3.0, 
7.0, and 9.0. The data obtained for the thermal unfolding transitions were fitted to a 
sigmoidal function (Figures 4.4a, 4.4b, and 4.4c), and the mid-point of each fit was 
defined as the thermal unfolding temperature (Tm). Tms obtained for PEGEC1 were 
compared to those obtained for EC1. PEGEC1 showed a higher Tm at each pH studied 
(Figure 4.4d). Thus, PEGEC1 has better thermal stability than EC1. 
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Figure 4.4a: Thermal unfolding profile of PEGEC1 compared to that of EC1 at pH 
3.0 obtained by plotting the CD signal at 218 nm against the corresponding 
temperature. 
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 Figure 4.4b: Thermal unfolding profile of PEGEC1 compared to that of EC1 at pH 
7.0 obtained by plotting the CD signal at 218 nm against the corresponding 
temperature. 
 
 
 
 
 
 
 
 
 154
10 20 30 40 50 60 70
-0.2
0.0
0.2
0.4
0.6
0.8
1.0
1.2
1.4
Fr
ac
tio
n 
of
 p
ro
te
in
 u
nf
ol
de
d
Temperature (°C)
PEGEC1
EC1
 Figure 4.4c: Thermal unfolding profile of PEGEC1 compared to that of EC1 at pH 
9.0 obtained by plotting the CD signal at 218 nm against the corresponding 
temperature. 
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Figure 4.4d: A comparison of the unfolding temperatures (Tms) for PEGEC1 and EC1 
at pH 3.0, 7.0, and 9.0 after fitting the CD thermal unfolding profiles in 4.4a, 4.4b, 
and 4.4c, to sigmoidal functions. 
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4.3.2.2. Intrinsic fluorescence emission spectroscopy results: Intrinsic 
fluorescence emission spectra of PEGEC1 were obtained at pH 3.0, 7.0, and 9.0 
between 305 nm and 405 nm after excitation at 295 nm. These spectra were compared 
to the corresponding spectra of EC1. The wavelength of maximum emission at pH 3.0 
was 339.87 ± 0.03 nm for PEGEC1, similar to that for EC1 (339.93 ± 0.04 nm) at pH 
3.0 (Figure 4.5a). At pH 7.0, it was 339.83 ± 0.05 nm, similar to that of EC1 (339.27 
± 0.03 nm) at pH 7.0 (Figure 4.5b).  At pH 9.0, however, there was a small but 
significant difference in the wavelengths of maximum emission of PEGEC1 (339.97 
± 0.02 nm) and EC1 (341.31 ± 0.03 nm) (Figure 4.5c). A possible explanation for this 
difference at pH 9.0 is that the PEG interacts with at least one of the two Trp residues, 
probably the Trp6 residue that is near the site of PEGylation at the Cys13 residue. 
The presence of the bulky PEG group near the Cys13 residue makes Trp6 less 
exposed to the solvent in PEGEC1 than in EC1.  
 
 
 
 
 
 
 
 
 
 157
0
100000
200000
300000
400000
500000
600000
700000
800000
900000
1000000
305 315 325 335 345 355 365 375 385 395 405
Wavelength (nm)
E
m
iss
io
n 
(c
ou
nt
s/
se
c) PEGEC1
EC1
 
Figure 4.5a: Tertiary structure studies of PEGEC1 using intrinsic fluorescence 
emission spectroscopy. The emission spectra of PEGEC1 are compared to those of 
EC1 at pH 3.0. PEGEC1 and EC1 show similar tertiary structures. 
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Figure 4.5b: Tertiary structure studies of PEGEC1 using intrinsic fluorescence 
emission spectroscopy. The emission spectra of PEGEC1 are compared to those of 
EC1 at pH 7.0. PEGEC1 and EC1 show similar tertiary structures. 
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Figure 4.5c: Tertiary structure studies of PEGEC1 using intrinsic fluorescence 
emission spectroscopy. The emission spectra of PEGEC1 are compared to those of 
EC1 at pH 9.0. PEGEC1 and EC1 show similar tertiary structures. 
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The thermal unfolding transition of PEGEC1 was followed also by monitoring the 
shift in wavelength of maximum emission with increasing temperature. At pH 3.0, the 
thermal unfolding profiles of PEGEC1 and EC1 appear similar (Figure 4.6a), with no 
transition observed until 75 °C. At pH 7.0, the thermal unfolding profiles of PEGEC1 
and EC1 were different, with PEGEC1 showing a transition to higher wavelengths (~ 
350 nm) than EC1 (~346 nm) (Figure 4.6b). The transition temperature of PEGEC1 
was estimated as 47.38 ± 1.40 °C, about 5 °C higher than that of EC1 (42.73 ± 
0.60 °C). At pH 9.0, the thermal unfolding profiles for PEGEC1 and EC1 were 
similar (Figure 4.6c). The transition temperature of PEGEC1 was estimated to be 
40.58 ± 0.95 °C, which is not significantly different than the Tm obtained for EC1 
(38.34 ± 1.02 °C). 
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Figure 4.6a: Thermal unfolding profiles of PEGEC1 compared to those of EC1 at pH 
3.0 obtained by plotting the wavelength of maximum emission after excitation at 295 
nm against the corresponding temperature.  
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Figure 4.6b: Thermal unfolding profiles of PEGEC1 compared to those of EC1 at pH 
7.0 obtained by plotting the wavelength of maximum emission after excitation at 295 
nm against the corresponding temperature. 
 
 
 
 
 
 
 
 163
0 10 20 30 40 50 60 70 80 90
338
340
342
344
346
348
350
352
W
av
el
en
gt
h 
(n
m
)
Temperature (°C)
PEGEC1
EC1
 Figure 4.6c: Thermal unfolding profiles of PEGEC1 compared to those of EC1 at pH 
7.0 obtained by plotting the wavelength of maximum emission after excitation at 295 
nm against the corresponding temperature. 
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4.4. Discussion 
We successfully synthesized and purified the PEGylated product of EC1 
(PEGEC1). The PEGylation was accomplished by nucleophilic attack on the 
maleimide group of PEG by the thiol group of the Cys13 residue of the EC1 protein. 
This reaction produced a homologous mono-PEGylated product as determined by 
HPLC and mass spectrometry. PEGylation of the Cys residues of proteins has been 
employed previously to improve their in vitro and in vivo stabilities.13-17 It has been 
proposed that protein stabilization with linear PEG is generally a result of the 
formation of a polymer shell around the protein that recruits water to form an outer 
water shell that minimizes intermolecular protein interactions.10 PEGylation at several 
sites on a protein with higher molecular weight branched PEGs (as opposed to linear 
PEG) can shield the entire protein molecule. The hydrophobic and hydrophilic 
portions of PEG can interact with the hydrophobic and hydrophilic regions, 
respectively of the protein conjugated to the PEG. This is how a PEG-shell is created 
around the protein surface. This shell can mask the surface interactions between 
protein molecules.  Because a 5,000 Da linear PEG is used in PEGEC1, there is a 
possibility that the PEG group may not be large enough to form a shell around the 
entire EC1 molecule. This could be significant because the peptide sequences (HAV 
and ADT) of EC1 which have been shown to modulate E-cadherin interactions are 
located on the surface of EC1 opposite the surface of the PEGylation site. This aspect 
is discussed in more detail later in this chapter. The X-ray structure of EC1 indicates 
that the surface of EC1 where the Cys13 residue is located is also the surface that is 
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involved in dimerization of EC1. The Trp6 residue on this surface is involved in the 
formation of domain swapped physical dimers; in the domain swapping process, the 
Trp6 residue of one EC1 domain is buried in a hydrophobic pocket of another EC1 
domain. Thus, we propose that the presence of the PEG near the domain swapping 
region may prevent the formation of physical and chemical dimers of EC1. 
Chemical stability studies at 70 °C showed that PEGEC1 was stable after 4 h at 
pH 3.0, 7.0, and 9.0. In contrast, the unmodified EC1 protein can undergo 
precipitation and peptide bond hydrolysis. The alkylated EC1 protein (EC1-IN) has a 
better stability at pH 7.0 and 9.0 than does the parent EC1; at pH 3.0, however, EC1-
IN undergoes precipitation. Thus, these results suggest that, of all the methods 
examined so far, PEGylation is the best strategy for stabilizing the EC1 protein. It is 
also possible that the PEGylation of EC1 decreases the dynamic properties of 
PEGEC1, which contributes to the decrease in the hydrolysis reaction; this proposal 
needs further investigation.  
Although PEGylation improves the physical and chemical stability of EC1, this 
modification may alter the ability of EC1 to inhibit E-cadherin-mediated cell-cell 
adhesion. Our previous studies have indicated that peptides containing the His47–
Ala48–Val49 (HAV) and Ala83–Asp84–Thr85 (ADT) sequences derived from EC1 
inhibit E-cadherin-mediated cell-cell adhesion. The HAV and ADT sequences are 
located on a surface of EC1 different from that of the PEGylation site. Therefore, 
PEGylation is not expected to alter the activity of the HAV and ADT sequences. It 
has been suggested that EC1 could have two homophilic binding surfaces. One is the 
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domain-swapping N-terminal region and the other is the region where the HAV and 
ADT sequences are located. In the future, the activity of PEGEC1 can be studied to 
determine the importance of either the domain swapping or the HAV/ADT region of 
EC1 in inhibiting the E-cadherin-mediated cell-cell adhesion. 
PEGylation of EC1 has some impact on the secondary and tertiary structure of 
EC1. Far UV CD studies showed some minor differences between CD spectra of 
PEGEC1 and EC1 at pH 3.0. At pH 7.0 and 9.0, however, no substantial differences 
were observed between the CD spectra of PEGEC1 and EC1. These results suggest 
that compared to EC1-IN, PEGEC1 is less sensitive to pH changes. Studies of other 
PEGylated proteins also show that PEGylation does not change the secondary 
structure of the protein.18,19 The thermal unfolding profiles determined by CD 
spectroscopy suggest that PEGEC1 was significantly more stable than EC1 with an 
increase in its Tm by 5.1 °C at pH 3.0, 4.0 °C at pH 7.0, and 7.7 °C at pH 9.0 after 
PEGylation. It was also found that the tertiary structure of PEGEC1 studied at pH 3.0, 
7.0, and 9.0 was similar to that of EC1.  
In conclusion, PEGylation of EC1 improves its physical and chemical stability. 
Unlike the modified EC1-IN protein, PEGEC1 has a structure similar to that of the 
parent EC1 at different pH values. In the future, the biological activity of PEGEC1 
will be compared to that of EC1-IN and EC1 in inhibiting E-cadherin-mediated cell-
cell adhesion in in vitro cell culture systems developed in our laboratory. 
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5.1. Summary 
A large number of peptides and proteins currently are being investigated for their 
potential as therapeutic agents. One of the major obstacles to their development as 
future drugs is their inability to permeate biological barriers such as the intestinal 
mucosa and the blood brain barrier. The possibility of improving the paracellular 
transport of these drugs across such barriers currently is being studied. The 
intercellular junctions of these biological barriers contain a variety of protein-protein 
interactions, which function as cell adhesion mechanisms and act as ‘filters’ to the 
transport of large molecules through the junctions. E-cadherin is one such 
transmembrane protein located in the adherens region of the intercellular junctions of 
epithelial tissue in the intestinal mucosa as well as the blood-brain barrier. 
Understanding the mechanism of E-cadherin-mediated homophilic interactions is 
essential for developing strategies to modulate them. Studies have shown that the 
EC1 domain of E-cadherin plays an important role in the selectivity of these 
interactions. Thus, it is desirable to study the interaction of the EC1 domain with 
other EC domains in in vitro cell culture systems such as Caco-2 cell monolayers, 
which are mediated by E-cadherin. We therefore decided to express the recombinant 
human EC1 domain and study its stability.    
In Chapter 2, we developed a system to express recombinant human EC1 in E. 
coli cells. This system provided a yield approximately 10 times higher than that of the 
system previously in place. It had also been shown previously that EC1 formed 
disulfide-mediated dimers that, in turn, formed physical oligomers. We conducted 
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studies to evaluate the effect of this covalent dimerization and physical 
oligomerization on the structure and stability of EC1. Short-term chemical stability 
studies, also known as “accelerated stability testing”, were performed by incubating 
the protein under different pH conditions at high temperatures and quantifying the 
amount of protein remaining using HPLC. We found that at 37 °C and 70 °C, a 
significant amount of EC1 was lost to precipitation and hydrolysis of the peptide 
bond between the D93 and P94 residues. Addition of dithiothreitol (DTT), a disulfide 
reducing agent, to EC1 before performing the accelerated stability tests significantly 
decreased the level of precipitation as well as the peptide bond hydrolysis. We 
concluded that disulfide-mediated dimerization and physical oligomerization of EC1 
reduced the stability of EC1. This result hinted at a difference in the structures of EC1 
monomer, dimer, and oligomers. We sought to clarify this possibility by running 
molecular dynamics simulations of the EC1 monomer and dimer. These simulation 
studies revealed that disulfide bond formation between the Cys13 residues of two 
EC1 monomers is a facile reaction. The resulting covalent dimer is structurally 
different than the monomer and also has higher flexibility. The increased dynamics of 
the dimer possibly expose the D93–P94 peptide bond to the solvent, thereby making 
it more susceptible to hydrolysis. To confirm the molecular dynamics simulation 
results, we investigated the change in the structure of EC1 due to covalent 
dimerization and physical oligomerization by incubating EC1 for a relatively long 
period (28 days) at 4 °C. After incubation for 14 and 28 days, the changes in its 
secondary and tertiary structures were monitored by far UV circular dichroism (CD) 
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spectroscopy and intrinsic fluorescence emission spectroscopy, respectively. The 
results revealed that the secondary structure of EC1 changed significantly after 14 to 
28 days. When DTT was added to the EC1 solution, however, before repeating the 
experiments under the same conditions, no changes were detected in the CD spectra. 
The tertiary structure studies revealed essentially the same results. The intrinsic 
fluorescence emission spectra of EC1 changed substantially after 28 days incubation 
at 4 °C, but those of the DTT-supplemented EC1 solution did not.  We therefore 
concluded that the disulfide-mediated dimerization and physical oligomerization of 
EC1 are the main routes of its degradation. 
In Chapter 3, we modified the Cys13 thiol of EC1 irreversibly by alkylating it 
with iodoacetamide. This modification can serve the purpose of maintaining EC1 in 
its monomeric form without DTT. This is particularly useful because the addition of 
DTT may interfere with cell culture systems. An eventual goal of stabilizing EC1 is 
to study the biological activity of the stabilized EC1 in cell culture systems. The 
alkylated EC1 (EC1-IN) was resistant to hydrolysis of its D93–P94 peptide bond. The 
secondary and tertiary structures of EC1-IN are similar to those of EC1 at pH 7.0. An 
important finding was that the secondary and tertiary structures of EC1-IN did not 
change significantly after long-term incubation at 4 °C, unlike the structure of EC1. 
This result would be expected because the irreversible modification of the thiol group 
in EC1-IN does not permit intermolecular disulfide formation between EC1 
monomers. At pH 3.0 and 9.0, however, EC1-IN showed secondary structures 
different from those of EC1. Although not unexpected, it provided us with the 
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challenge of producing a thiol derivative of EC1 that retains a secondary structure 
similar to EC1 over a wide range of pH. Maintaining the secondary structure of EC1 
after modification of its thiol could be important for retaining its biological activity. 
Chapter 4 describes our results in attempting to make another thiol derivative of 
EC1 that is even more stable. In this case, the thiol group of Cys13 in EC1 was 
reacted with a maleimide-activated polyethylene glycol (M.W. 5,000 Da). The 
PEGylated EC1 (PEGEC1) showed a secondary structure very similar to that of EC1 
at pH 3.0, 7.0, and 9.0. Moreover, PEGEC1 has higher thermal stability than the 
parent EC1 and also is resistant to peptide bond hydrolysis at 70 °C. PEGEC1 has a 
structure similar to that of the parent EC1 at different pH values; this is in contrast to 
EC1-IN. 
In summary, EC1 provided us with a model for studying disulfide-mediated 
protein degradation. Using various strategies, we were able to dramatically inhibit 
this degradation by the production of a PEGylated derivative.  
 
 
5.2. Future work 
As mentioned previously, the long-term goal behind our attempts at stabilizing 
EC1 is to study its in vitro biological activity as well as its binding properties to other 
EC domains of E-cadherin. Our studies on the stability of EC1 provide useful 
information for the handling and storage of EC1. Because EC1-IN retained its 
secondary structure at pH 7.0, this molecule is expected to retain its biological 
activity. EC1-IN can also be studied for its interaction with peptides derived from E-
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cadherin. Different EC domains can be immobilized on solid surfaces, and their 
binding to EC1-IN in solution can be studied using techniques such as surface 
plasmon resonance. Alternatively, multi-dimensional NMR spectroscopy can be used 
to study the interaction of 15N-labeled EC1-IN with peptides derived from the EC 
domains. Furthermore, the interaction of EC1-IN with the entire extracellular segment 
of E-cadherin in living cells also can be studied in cell culture systems such as Caco-2 
cell monolayers.  
 
5.3. Final comments 
It has been difficult to handle and study EC1 due to the heterogeneity produced by 
its spontaneous dimerization mediated by intermolecular disulfide bonds, followed by 
its physical oligomerization. By blocking its covalent dimerization and physical 
oligomerization through modification of its Cys13 thiol, we have provided EC1 
derivatives that can replace EC1 in future studies. 
  
 
 
 
 
 
 
 
 
